WO2012110778A2

WO2012110778A2 - Feed additive composition

Info

Publication number: WO2012110778A2
Application number: PCT/GB2012/050124
Authority: WO
Inventors: Luis Fernando Romero MILLÁN
Original assignee: Dupont Nutrition Biosciences Aps
Priority date: 2011-02-18
Filing date: 2012-01-19
Publication date: 2012-08-23
Also published as: JP2014507946A; AU2012216898A1; AR084893A1; EP2675286B1; BR112013020684A2; AU2016201761B2; AU2016201761A1; BR112013020684B1; GB201102857D0; WO2012110778A3; ZA201305269B; CN103533843A; US20190076488A1; CA2825618A1; US20140234279A1; CA2825618C; US10695384B2; DK2675286T3; ES2621137T3; EP2675286A2

Abstract

A feed additive composition comprising a direct fed microbial in combination with a protease, a xylanase, an amylase and a phytase, and a method for improving the performance of a subject or for improving digestibility of a raw material in a feed (e.g. nutrient digestibility, such as amino acid digestibility), or for improving nitrogen retention, or for avoiding the negative effects of necrotic enteritis or for improving feed conversion ratio (FCR) or for improving weight gain in a subject or for improving feed efficiency in a subject or for modulating (e.g. improving) the immune response of the subject or for promoting the growth of beneficial bacteria in the gastrointestinal tract of a subject, which method comprising administering to a subject a direct fed microbial in combination with a protease, a xylanase, an amylase and a phytase.

Description

FEED ADDITIVE COMPOSITION

FIELD OF INVENTION

The present invention relates to methods for improving feed compositions using a direct fed microbial in combination with a specific combination of enzymes, and to a feed additive composition comprising a direct fed microbial in combination with a specific combination of enzymes. The present invention further relates to uses and kits. BACKGROUND OF THE INVENTION

Supplemental enzymes are used as additives to animal feed, particularly poultry and swine feeds, as a means to improve nutrient utilization and production performance characteristics. Enzyme blends are available to improve the nutritional value of diets containing soybean meal, animal protein meals, or high fibre food by-products.

The concept of direct fed microbials (DFM) involves the feeding of beneficial microbes to animals, such as dairy cattle when they are under periods of stress (disease, ration changes, environmental or production challenges). Probiotics is another term for this category of feed additives. Probiotics or DFM have been shown to improve animal performance in controlled studies. DFM including direct fed bacteria and or yeast-based products.

Although combinations of DFMs with some enzymes have been contemplated, the interaction between DFMs and enzyme has never been fully understood. The present invention relates to novel specific combinations which surprisingly significantly improve production performance characteristics of animals. SUMMARY OF INVENTION

A seminal finding of the present invention is that a DFM in combination with a protease, xylanase, amylase and phytase has significant beneficial effects on the performance of an animal.

In particular, a seminal finding of the present invention is that a DFM in combination with a protease, xylanase, amylase and phytase has significant beneficial effects on the performance of an animal, including improving one or more of the following: feed conversion ratio (FCR), ability to digest a raw material (e.g. nutrient digestibility, such as amino acid digestibility), nitrogen retention, survival, carcass yield, growth rate, weight gain, feed efficiency animals resistance to necrotic enteritis, immune response of the subject, or the growth of beneficial bacteria in the gastrointestinal tract of a subject.

Another surprising effect of the present invention is that it can reduce nutrient excretion in manure (e.g. reduce nitrogen and phosphorus) content of a subject's manure.

In one aspect, the present invention provides a feed additive composition comprising (or consisting essentially of or consisting of) a direct fed microbial in combination with a protease, a xylanase, an amylase and a phytase.

In another aspect, the present invention provides a method for improving the performance of a subject or for improving digestibility of a raw material in a feed (e.g. nutrient digestibility, such as amino acid digestibility), or for improving nitrogen retention, or for avoiding the negative effects of necrotic enteritis or for improving feed conversion ratio (FCR) or for improving weight gain in a subject or for improving feed efficiency in a subject or for modulating (e.g. improving) the immune response of the subject or for promoting the growth of beneficial bacteria in the gastrointestinal tract of a subject or for reducing populations of pathogenic bacteria in the gastrointestinal tract of a subject, or for reducing nutrient excretion in manure, which method comprising administering to a subject a direct fed microbial in combination with a protease, a xylanase, an amylase and a phytase.

A yet further aspect of the present invention is use of a direct fed microbial in combination with a protease, a xylanase, an amylase and a phytase for improving the performance of a subject or for improving digestibility of a raw material in a feed (e.g. nutrient digestibility, such as amino acid digestibility) or for improving nitrogen retention) or for avoiding the negative effects of necrotic enteritis or for improving feed conversion ratio (FCR) or for improving weight gain in a subject or for improving feed efficiency in a subject or for modulating (e.g. improving) the immune response of the subject or for promoting the growth of beneficial bacteria in the gastrointestinal tract of a subject or for reducing populations of pathogenic bacteria in the gastrointestinal tract of a subject, or for reducing nutrient excretion in manure.

In a further aspect of the present invention there is provided a kit comprising a direct fed microbial, a protease, a xylanase, an amylase, a phytase (and optionally at least one vitamin and/or optionally at least one mineral) and instructions for administration.

In another aspect the present invention provides a method of preparing a feed additive composition, comprising admixing a direct fed microbial with a protease, a xylanase, an amylase and a phytase and (optionally) packaging. In a yet further aspect the present invention provides feed or feedstuff comprising a feed additive composition comprising (or consisting essentially of or consisting of) a direct fed microbial in combination with a protease, a xylanase, an amylase and a phytase.

A premix comprising a feed additive composition comprising (or consisting essentially of or consisting of) a direct fed microbial in combination with a protease, a xylanase, an amylase and a phytase, and at least one mineral and/or at least one vitamin.

In another aspect, the present invention provides a method of preparing a feedstuff comprising admixing a feed component with a feed additive composition comprising (or consisting essentially of or consisting of) a direct fed microbial in combination with a protease, a xylanase, an amylase and a phytase.

In a further aspect, the present invention relates to a feed additive composition for preventing and/or treating coccidiosis and/or necrotic enteritis in a subject.

The present invention yet further provides a method of preventing and/or treating necrotic enteritis and/or coccidiosis wherein an effective amount of a feed additive composition according to the present invention is administered to a subject.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows that a combination of DFM (Enviva Pro® available from Danisco A/S) with a combination of a xylanase (e.g. an endo-xylanase from Trichoderma xylanase), an amylase (e.g. a Bacillus licheniformis alpha-amylase), a protease (e.g. Bacillus subtilis protease) and a phytase (e.g. 500FTU/k.g of Phyzyme XP (an E. coli phytase) available from Danisco A/S) significantly improved (reduced) necrotic enteritis lesion scores in the gut of the animals compared with the challenged control. In some embodiments the xylanase, amylase and protease may fomiulated together in AxtraXAP® [containing 2000 XU/kg feed of xylanase; 200 AU/kg feed of amylase and 4000 PU/kg feed of protease] also available from Danisco A/S).

Figure 2 shows that a combination of (Enviva Pro® available from Danisco A/S) with a combination of a xylanase (e.g. an endo-xylanase from Trichoderma xylanase), an amylase (e.g. a Bacillus licheniformis alpha-amylase), a protease (e.g. Bacillus subtilis protease) and a phytase (e.g. 500FTU/kg of Phyzyme XP (an E. coli phytase) available from Danisco A/S) significantly improved Body weight gain (BW gain) in broiler chickens challenged with Clostridium perfringens compared with the challenged control - even resulting in a BW gain which was improved over a negative control (i.e. an unchallenged control). This was significantly better than any other combinations of enzymes such as either amylase and phytase or protease and phytase, and significantly better than DFM applied on the challenged control. In some embodiments the xylanase, amylase and protease may formulated together in A traXAP® [containing 2000 XU/kg feed of xylanase; 200 AU/kg feed of amylase and 4000 PU/kg feed of protease] also available from Danisco A/S). Pooled SEM=28.6

Figure 3 shows a combination of (Enviva Pro® available from Danisco A/S) with a combination of a xylanase (e.g. an endo-xylanase from Trichoderma xylanase), an amylase (e.g. a Bacillus licheniformis alpha-amylase), a protease (e.g. Bacillus subtUis protease) and a phytase (e.g. 500FTU/kg of Phyzyme XP (an coli phytase) available from Danisco A/S) significantly improved feed conversion ratio (FCR) (g feed intake/g BW gain) in broiler chickens challenged with Clostridium perfringens to the level of unchallenged birds. This was significantly better than other combinations of enzymes with the DFM such as either amylase and phytase or protease and phytase. In some embodiments the xylanase, amylase and protease may formulated together in AxtraXAP® [containing 2000 XU/kg feed of xylanase; 200 AU/kg feed of amylase and 4000 PU/kg feed of protease] also available from Danisco A/S).

Figure 4 shows relative mRNA expression of IFN-g used as marker of inflammation in the intestine, and shows that a combination of DFM (Enviva Pro®) with a combination of xylanase, amylase, protease and phytase (Avizyme 1502® available from Danisco A/S + 500FTU/kg of Phyzyme XP (an E. coli phytase) increased IFN-g expression at 1 1 days and reduced it at 20 days.

Figure 5 shows apparent ileal digestible energy (mCal/kg) and shows that a combination of DFM (Enviva Pro®) with a xylanase, amylase, protease and phytase (two different enzyme mixes were used the first was Avizyme 1502® available from Danisco A/S + 500FTU/kg of Phyzyme XP (an E. coli phytase); and the second was AxtraXAP [containing 2000 XU/kg feed of xylanase; 200 AU/kg feed of amylase and 4000 PU/kg feed of protease] also available from Danisco A/S + 500FTU/kg of Phyzyme XP (an E. coli phytase) significantly improved energy digestibility effects.

Figure 6 shows amino acid digestibility significantly improved with a combination of DFM (Enviva Pro®) with a xylanase, amylase, protease and phytase. The improvement of digestibility of the undigested fractions of amino acid at the ileal level with a combination of DMF with xylanase, amylase, protease and phytase was greater than the improvement of DFM alone or the combination of xylanase, amylase, protease and phytase without DFM. Figure 7 shows energy digestibility improved with a combination of DFM (Enviva Pro®) with a xylanase, amylase, protease and phytase.

Figure 8 shows nitrogen-corrected apparent metabolizable energy AMEn of dietary treatments fed to 17 to 21-d-old broiler chickens.

Figure 9 shows that a combination of DFM (Enviva Pro®) with a xylanase, amylase, protease and phytase (two di ferent enzyme mixes were used the first was Avizyme 1502® available from Danisco A/S + 500FTU/kg of Phyzyme XP (an E. coli phytase); and the second was AxtraXAP also available from Danisco A/S+ 500FTU/kg of Phyzyme XP (an E. coli phytase) significantly improved nitrogen retention.

Figure 10 shows that a combination of DFM (Enviva Pro®) with a xylanase, amylase, protease and phytase (Avizyme 1502® available from Danisco A/S + Phyzyme XP (an E. coli phytase)) significantly reduces the niRNA abundance of MUC-2 in the ileal mucosal scrapings at day 14 treated with an overdosed coccidian vaccine at hatch, compared to the challenged and unchallenged control treatments.

Figure 11 shows the amino acid sequence (SEQ ID No. 1) of a pepsin resistant alpha amylase from Bacillus licheniformis.

Figure 12 shows the nucleotide sequence (SEQ ID No. 2) of a pepsin resistant alpha amylase from Bacillus licheniformis.

Figure 13 shows the amino acid sequence (SEQ ID No. 3) of a pepsin resistant alpha amylase from Trichoderma reesei.

Figure 14 shows the nucleotide sequence (SEQ ID No. 4) of a pepsin resistant alpha amylase from Trichoderma reesei.

Figure 15 shows feed conversion ratio of broiler chickens at 48 d of age.

Figure 16 shows a heat map of expression profiles of genes of interest for all treatments for jejunum at 23 days of age.

Unchallenged control^ Unchallenged Control + phytase

CC = Challenged Control + phytase

CC+ Amylase = Challenged Control + phytase + amylase

CC+ XAP = Challenged Control + phytase + xylanase + amylase + protease

CC+ EP = Challenged Control + phytase + Enviva Pro

CC+ EP + Amylase = Challenged Control + phytase + amylase + Enviva Pro

CC+ EP + XAP = Challenged Control + phytase + xylanase + amylase + protease + Enviva

Pro. Figure 17 shows a heat map of expression profile of chicken alpha amylase for all treatments in pancreas at 23 days of age.

Unchallenged control^"" Unchallenged Control + phytase

CC ^■ Challenged Control + phytase

CC+ Amylase = Challenged Control + phytase + amylase

CC+ XAP = Challenged Control -+ phytase + xylana.se + amylase + protease

CC+ EP = Challenged Control + phytase + Enviva Pro

CC+ EP -rAmylasc = Challenged Control + phytase + amylase + Enviva Pro

CC+ EP + XAP = Challenged Control + phytase + xylanase + amylase + protease + Enviva Pro.

Figure 18 shows apparent metabolizable energy corrected by nitrogen retention (AME_n) of 21 d old broiler chickens. Effect of DFM; PO.001 ; Effect of Enzyme; PO.001 ; Effect of DFM x Enzyme; P-0.27; Pooled SEM=32 kcal.

Figure 19 shows feed conversion ratio (FCR) of broiler chickens in a necrotic enteritis challenge model (Pooled SEM: 0.015).

Figure 20 shows relative proportion of Lactobacillus spp. at 2 Id in jejunum in broiler chickens, ChSq O.0001.

DETAILED DESCRIPTION OF THE INVENTION

Preferably each of the enzymes used in the present invention are exogenous to the DFM. In other words the enzymes are preferably added to or admixed with the DFM.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Singleton, et al, DICTIONARY OF MICROBIOLOGY AND MOLECULAR BIOLOGY, 20 ED., John Wiley and Sons, New York (1994), and Hale & Marham, THE HARPER COLLINS DICTIONARY OF BIOLOGY, Harper Perennial, NY (1991) provide one of skill with a general dictionary of many of the terms used in this disclosure. This disclosure is not limited by the exemplary methods and materials disclosed herein, and any methods and materials similar or equivalent to those described herein can be used in the practice or testing of embodiments of this disclosure. Numeric ranges are inclusive of the numbers defining the range. Unless otherwise indicated, any nucleic acid sequences are written left to right in 5' to 3' orientation; amino acid sequences are written left to right in amino to carboxy orientation, respectively.

The headings provided herein are not limitations of the various aspects or embodiments of this disclosure which can be had by reference to the specification as a whole. Accordingly, the terms defined immediately below are more fully defined by reference to the specification as a whole.

Amino acids are referred to herein using the name of the amino acid, the three letter abbreviation or the single letter abbreviation.

The term "protein", as used herein, includes proteins, polypeptides, and peptides.

As used herein, the term "amino acid sequence" is synonymous with the term "polypeptide" and/or the tenia "protein". In some instances, the term "amino acid sequence" is synonymous with the term "peptide". In some instances, the term "amino acid sequence" is synonymous with the term "enzyme".

The terms "protein" and "polypeptide" are used interchangeably herein. In the present disclosure and claims, the conventional one-letter and three-letter codes for amino acid residues may be used. The 3-letter code for amino acids as defined in conformity with the IUPACIUB Joint Commission on Biochemical Nomenclature (JCBN). It is also understood that a polypeptide may be coded for by more than one nucleotide sequence due to the degeneracy of the genetic code.

Other definitions of terms may appear throughout the specification. Before the exemplary embodiments are described in more detail, it is to understand that this disclosure is not limited to particular embodiments described, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present disclosure will be limited only by the appended claims. Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limits of that range is also specifically disclosed. Each smaller range between any stated value or intervening value in a stated range and any other stated or intervening value in that stated range is encompassed within this disclosure. The upper and lower limits of these smaller ranges may independently be included or excluded in the range, and each range where either, neither or both limits are included in the smaller ranges is also encompassed within this disclosure, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in this disclosure.

It must be noted that as used herein and in the appended claims, the singular forms "a", "an", and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "an enzyme" includes a plurality of such candidate agents and reference to "the feed" includes reference to one or more feeds and equivalents thereof known to those skilled in the art, and so forth.

The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that such publications constitute prior art to the claims appended hereto.

The enzymes for use in the present invention can be produced either by solid or submerged culture, including batch, fed-batch and continuous-flow processes. Culturing is accomplished in a growth medium comprising an aqueous mineral salts medium, organic growth factors, the carbon and energy source material, molecular oxygen, and, of course, a starting inoculum of one or more particular microorganism species to be employed.

Direct Fed Microbial (DFM)

The term "microbial" herein is used interchangeably with "microorganism".

Preferably the DFM comprises a viable microorganism. Preferably the DFM comprises a viable bacterium or a viable yeast or a viable fungi.

In one preferred embodiment the DFM comprises a viable bacteria. The term "viable microorganism" means a microorganism which is metabolically active or able to differentiate. In one embodiment the DFM may be a spore forming bacterium and hence the term DFM may be comprised of or contain spores, e.g. bacterial spores. Therefore in one embodiment the term "viable microorganism" as used herein may include microbial spores, such as endo spores or conidia. In another embodiment the DFM in the feed additive composition according to the present invention is not comprised of or does not contain microbial spores, e.g. endospores or conidia.

The microorganism may be a naturally occurring microorganism or it may be a transformed microorganism. The microorganism may also be a combination of suitable microorganisms.

In some aspects, the DFM according to the present invention may be one or more of the following: a bacterium, a yeast or a fungi.

Preferably the DFM according to the present invention is a probiotic microorganism.

In the present invention, the term direct fed microbial (DFM) encompasses direct fed bacteria, direct fed yeast, direct fed yeast and combinations thereof.

Preferably the DFM is a direct fed bacterium.

Preferably the DFM is a combination comprising two or more bacteria, e.g. three or more or four or more; or the DFM is a combination comprising two or more bacterial strains, e.g. three or more or four or more. Preferably the bacterium or bacteria is or are isolated.

Suitably the DFM may comprise a bacterium from one or more of the following genera: Lactobacillus, Lactococcus, Streptococcus, Bacillus, Pediococcus, Enterococcus, Leuconostoc, Carnobacterium, Propionibacterium, Bifidobacterium, Clostridium and Megasphaera and combinations thereof.

In one embodiment the DFM may be selected from the following Bacillus spp: Bacillus subtilis, Bacillus cereus, Bacillus licheniformis and Bacillus amyloliquefaciens.

In one embodiment the DFM may be a combination comprising two or more Bacillus strains.

In one embodiment the DFM may be a combination of two or more the Bacillus subtilis strains 3A-P4 (PTA-6506); 15A-P4 (PTA-6507); 22C-P1 (PTA-6508); 2084 (NRRL B- 500130); LSSA01 (NRRL-B-50104); BS27 (NRRL B-50105); BS 18 (NRRL B-50633); and BS 278 (NRRL B-50634).

Strains 3A-P4 (PTA-6506), 15A-P4 (PTA-6507) and 22C-P 1 (PTA-6508) are publically available from American Type Culture Collection (ATCC).

Strains 2084 (NRRL B-500130); LSSA01 (NRRL-B-50104); BS27 (NRRL B-50105) are publically available from the Agricultural Research Service Culture Collection (NRRL). Strain Bacillus subtilis LSSA01 is sometimes referred to as B. subtilis 8.

These strains are taught in US 7, 754, 469 B2.

Bacillus subtilis BS 18 and Bacillus subtilis BS 278 were deposited by Andy Madisen of W227 N752 Westmound Dr. Waukesha, WI 53186, USA or Danisco USA Inc. of W227 N752 Westmound Dr. Waukesha, WI 53186, USA under the Budapest Treaty at the Agricultural Research Service Culture Collection (NRRL) at 1815 North University Street, Peoria, Illinois 61604, United States of America, under deposit numbers NRRL B-50633 and NRRL B-50634, respectively on 9 January 2012. Andy Madisen of W227 N752 Westmound Dr. Waukesha, WI 53186, USA and Danisco USA Inc. of W227 N752 Westmound Dr. Waukesha, WI 53186, USA authorise Danisco A/S of Langebrogade 1 , PO Box 17, DK-1001, Copenhagen K, Denmark to refer to these deposited biological materials in this patent application and have given unreserved and irrevocable consent to the deposited material being made available to the public. In some embodiments the DFM may be a combination comprising the Bacillus subtilis strains as detailed in the table below:

In one embodiment the DFM may be selected from the following Lactococcus spp: Laciococcus cremoris and Lactococcus laclis and combinations thereof.

In one embodiment the DFM may be selected from the following Lactobacillus spp: Lactobacillus buchneri, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus kefiri, Lactobacillus bifidus, Lactobacillus brevis, Lactobacillus helveticus, Lactobacillus paracasei, Lactobacillus rhamnosus, Lactobacillus salivarius, Lactobacillus curvaius, Lactobacillus bulgaricus, Lactobacillus sakei, Lactobacillus reuteri, Lactobacillus fermentum, Lactobacillus farciminis, Lactobacillus lactis, Lactobacillus delbreuckii, Lactobacillus plantarum, Lactobacillus par aplant arum, Lactobacillus farciminis, Lactobacillus rhamnosus, Lactobacillus crispatus, Lactobacillus gasseri, Lactobacillus johnsonii and Lactobacillus jensenii, and combinations of any thereof.

In one embodiment the DFM may be selected from the following Bifidobacteria spp: Bifidobacterium lactis, Bifidobacterium bifidium, Bifidobacterium longum, Bifidobacterium animalis, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium catenulatum, Bifidobacterium pseudocatenulatum, Bifidobacterium adolescentis, and Bifidobacterium angulatum, and combinations of any thereof. Suitably the DFM may comprise a bacterium from one or more of the following species: Bacillus subtilis, Bacillus licheniformis, Bacillus amyloliquefaciens, Enterococcus , Enterococcus spp, and Pediococcus spp, Lactobacillus spp, Bifidobacterium spp, Lactobacillus acidophilus, Pediococsus acidilactici, Lactococcus lactis, Bifidobacterium. bifidum, Bacillus subtilis, Propionibacterium thoenii, Lactobacillus farciminis, Lactobacillus rhamnosus, Megasphaera elsdenii, Clostridium butyricum, Bifidobacterium animalis ssp. animalis, Lactobacillus reuteri, Bacillus cereus, Lactobacillus salivarius ssp. Salivarius, Propionibacteria sp and combinations thereof. The direct fed bacterium used in the present invention may be of the same type (genus, species and strain) or may comprise a mixture of genera, species and/or strains.

Suitably the DFM according to the present invention may be one or more of the products or the microorganisms contained in those products as in the Table below:

Product Name Company Microor«anisin(s) Symbiotic ingredients

Enviva Pro®, Danisco A/S Bacillus subtilis strain 2084 Accession

(formerly No. NRR1 B-50013,

known as Bacillus subtilis strain LSSAOl

AvicoiT®) Accession No. NRR I . B-50104 and

Bacillus subtilis strain 15A-P4 ATCC

Accession No. PTA-6507

Calsporin® Calpis - Bacillus subtilis Strain C3102

Japan

Clostat® Kemin Bacillus subtilis Strain PB6

Industries

Inc.

Cylactin® DSM Enterococcus NCIMB 10415 (SF68)

Gallipro® Chr. Hansen Bacillus subtilis Strain C3102

& A/S

GalliproMax®

Gallipro®Tect® Chr. Hansen Bacillus licheniformis

A/S Poultry star® Biomin, Inc Enterococcus and Pediococcus Fructo- oligosacchari des

Protexin® Protexin Int Lactobacillus, Bifidobacterium and

another

Proflora® Alphamia Bacillus subtilis strain QST 713 β-Mos

Inc. β-niannan oligosaccliari des and β- glucans

Ecobiol® & Norel S.A. Bacillus amyloliquefaciens CECT-5940

Ecobiol® Plus

Fortiflora® Enterococcus faecium SF68

BioPlus2B® DSM Bacillus subtilis and Bacillus

licheniformis

Lactiferm® Chr. Hansen Lactic acid bacteria 7

Enterococcus faecium

CSI® Danisco A/S Bacillus strain

Yea-Sacc® Alltech Saccharomyces cerevisiae

Biomin Biomin Enterococcus

IMB52®

Biomin C5® Biomin Pediococcus acidilactici,

Enterococcus ,

Bifidobacterium animalis ssp. animalis,

Lactobacillus reuteri

Lactobacillus salivarius ssp. salivarius

Biacton® ChemVet Lactobacillus farciminis

Oralin E1707® Chevita Enterococcus

GmBH

Probios-pioneer Chr Hansen Enterococcus (2 strains)

PDFM® Lactococcus lactis DSM 1 1037

Sorbiflore® Danisco Lactobacillus rhamnosus and

Animal Lactobacillus farciminis Nutrition

Animavit® KRKA Bacillus sublilis

Bonvital® Lactosan Enter ococcus

GmbH

Levucell SB Lallemand Saccharomyces cerevisiae

20®

Levucell SC 0 & Lallemand Saccharomyces cerevisiae

SC10® ME

Bactocell Lallemand Pediococcus acidilacti

ActiSaf® Le Saffre Saccharomyces cerevisiae

(formerly

BioSaf®)

Actisaf® SC47 Le Saffre Saccharomyces cerevisiae NCYC Sc47

Miya-Gold® Miyarisan Clostridium butyricum

Pharma

Fecinor and Norel S.A

Fecinor Plus® Enterococcus

InteSwine® ntegro Gida

ve Ticaret

AS

represented

by RM

Associates

Ltd Saccharomyces cerevisiae CYC R-625

BioSprint® ProSol SpA Saccharomyces cerevisia

Provita® Provita Enterococcus and

Lactobacillus rhamnosus

PepSoyGen-C® Regal BV Bacillus subtilis and

(Nutraferma) Aspergillus oryzae

Toyocerin® Rubinum Bacillus cereus

TOYOCERIN® Rubinum Bacillus cereus var. toyoi NCIMB

401 12/CNCM 1-1012 In one embodiment suitably the DFM may be Enviva Pro®. Enviva Pro® is commercially available from Danisco A/S and is a combination of Bacillus strain 2084 Accession No. NRR1 B-50013, Bacillus strain LSSAO l Accession No. NRRL B-501 04 and Bacillus strain 15A-P4 ATCC Accession No. PTA-6507 (as taught in US 7,754,469 B - incorporated herein by reference).

Suitably, the DFM may comprise a yeast from the genera: Saccharomyces spp.

Preferably the DFM to be used in accordance with the present invention is a microorganism which is generally recognised as safe and, which is preferably GRAS approved.

A skilled person will readily be aware of specific species and or strains of microorganisms from within the genera described herein which are used in the food and/or agricultural industries and which are generally considered suitable for animal consumption.

Preferably, the DFM used in accordance with the present invention is one which is suitable for animal consumption.

Advantageously, where the product is a feed or feed additive composition, the viable DFM should remain effective through the normal "sell-by" or "expiration" date of the product during which the feed or feed additive composition is offered for sale by the retailer. The desired lengths of time and normal shelf life will vary from feedstuff to feedstuff and those of ordinary skill in the art will recognise that shelf-life times will vary upon the type of feedstuff, the size of the feedstuff, storage temperatures, processing conditions, packaging material and packaging equipment.

In some embodiments it is important that the DFM is tolerant to heat, i.e. is thermotolerant. This is particularly the case where the feed is pelleted. Therefore in one embodiment the DFM may be a thermotolerant microorganism, such as a thermotolerant bacteria,_including for example Bacillus spp. In some embodiments it may be preferable that the DFM is a spore producing bacteria, such as Bacilli, e.g. Bacillus spp. Bacilli are able to from stable endospores when conditions for growth are unfavorable and are very resistant to heat, H, moisture and disinfectants. In one embodiment suitably the DFM may decrease or prevent intestinal establishment of pathogenic microorganism (such as Clostridium perfringens and/or E. coli and/or Salmonella spp and/or Campylobacter spp.).

The DFM according to the present invention may be any suitable DFM. In one embodiment the following assay "DFM ASSAY" may be used to determine the suitability of a microorganism to be a DFM. For the avoidance of doubt in one embodiment a DFM selected as an inhibitory strain (or an an li pathogen DFM) in accordance with the "DFM ASSAY" taught herein is a suitable DFM for use in accordance with the present invention, i.e. in the feed additive composition according to the present invention.

DFM ASSAY:

Tubes were seeded each with a representative pathogen from a representative cluster. Supernatant from a potential DFM grown aerobically or anaerobically was added to the seeded tubes and incubated.

After incubation, the optical density (OD) of the control and supernatant treated tubes was measured for each pathogen.

Colonies of (potential DFM) strains that produced a lowered OD compared with the control were classified as an inhibitory strain (or an antipathogen DFM).

The DFM assay as used herein is explained in more detail in US2009/0280090 - incorporated herein by reference.

Preferably the representative pathogen used in assay is one (or more) of the following: Clostridium, such as Clostridium perfringens and/or Clostridium difficile, and/or E. coli and/or Salmonella spp and/or Campylobacter spp. In one preferred embodiment the assay is conducted with one or more of Clostridium perfringens and/or Clostridium difficile and/or E. coli, preferably Clostridium perfringens and/or Clostridium difficile, more preferably Clostridium perfringens.

In one embodiment the DFM of the present invention is preferably an antipathogen.

The term "antipathogen" as used herein means the DFM counters an effect (negative effect) of a pathogen.

In one embodiment to determine if a DFM is an antipathogenic DFM the above mentioned DFM assay may be used. A DFM is considered to be an antipathogen or antipathogenic DFM if it is classed as an inhibitory strain in the above mentioned "DFM assay", for example when the pathogen is Clostridium perfringens.

In one embodiment the antipathogen DFM may be one or more of the following bacteria: Bacillus subtilis strain 2084 Accession No. NR L B-50013,

Bacillus subtilis strain LSSAO l Accession No. NRRL B-50104,

Bacillus subtilis strain 15A-P4 ATCC Accession No. PTA-6507,

Bacillus subtilis strain 3A-P4 ATCC Accession No. PTA-6506, and

Bacillus subtilis strain BS27 ATCC Accession No. NRRL B-50105.

For the avoidance of doubt these strains are available and are referred to in US 7,754,459 B.

In one embodiment the DFM used in accordance with the present invention is not Lactobacillus gasseri BNR 17 Strain Acc No. KCTC 10902BP as taught in WO2008/016214.

Preferably the DFM is not an inactivated microorganism.

In one embodiment the DFM as used here is a composition comprising one or more DFM microorganisms as described herein. The composition may additionally comprise the enzymes of the present invention. The composition can be fed to an animal as a direct-fed microbial (DFM). One or more carrier(s) or other ingredients can be added to the DFM. The DFM may be presented in various physical forms, for example, as a top dress, as a water soluble concentrate for use as a liquid drench or to be added to a milk replacer, gelatin capsule, or gels. In one embodiment of the top dress form, freeze-dried fermentation product is added to a carrier, such as whey, maltodextrin, sucrose, dextrose, limestone (calcium carbonate), rice hulls, yeast culture, dried starch, and/or sodium silico aluminate. In one embodiment of the water soluble concentrate for a liquid drench or milk replacer supplement, freeze-dried fermentation product is added to a water soluble carrier, such as whey, maltodextrin, sucrose, dextrose, dried starch, sodium silico aluminate, and a liquid is added to form the drench or the supplement is added to milk or a milk replacer. In one embodiment of the gelatin capsule form, freeze-dried fermentation product is added to a carrier, such as whey, maltodextrin, sugar, limestone (calcium carbonate), rice hulls, yeast culture dried starch, and/or sodium silico aluminate. In one embodiment, the bacteria and carrier are enclosed in a degradable gelatin capsule. In one embodiment of the gels form, freeze-dried fermentation product is added to a carrier, such as vegetable oil, sucrose, silicon dioxide, polysorbate 80, propylene glycol, butylated hydroxyanisole, citric acid, ethoxyquin, and/or artificial coloring to form the gel.

The DFM(s) may optionally be admixed with a dry formulation of additives including but not limited to growth substrates, enzymes, sugars, carbohydrates, extracts and growth promoting micro-ingredients. The sugars could include the following: lactose; maltose; dextrose; maltodextrin; glucose; fructose; mannose; tagatose; sorbose; raffinose; and galactose. The sugars range from 50-95%, either individually or in combination. The extracts could include yeast or dried yeast fermentation solubles ranging from 5-50%. The growth substrates could include: trypticase, ranging from 5-25%; sodium lactate, ranging from 5-30%; and, Tween 80, ranging from 1 -5%. The carbohydrates could include mannitol, sorbitol, adonitol and arabitol. The carbohydrates range from 5-50% individually or in combination. The micro-ingredients could include the following: calcium carbonate, ranging from 0.5-5.0%; calcium chloride, ranging from 0.5-5.0%; dipotassium phosphate, ranging from 0.5-5.0%; calcium phosphate, ranging from 0.5-5.0%; manganese proteinate, ranging from 0.25-1.00%; and, manganese, ranging from 0.25- 1.0%.

To prepare DFMs described herein, the culture(s) and carrier(s) (where used) can be added to a ribbon or paddle mixer and mixed for about 15 minutes, although the timing can be increased or decreased. The components are blended such that a uniform mixture of the cultures and carriers result. The final product is preferably a dry, flowable powder. The DFM(s) or composition comprising same can then be added to animal feed or a feed premix, added to an animal's water, or administered in other ways known in the art (preferably simultaneously with the enzymes of the present invention). A feed for an animal can be supplemented with one or more DFM(s) described herein or with a composition described herein.

By "a mixture of at least two strains," is meant a mixture of two, three, four, five, six or even more strains. In some embodiments of a mixture of strains, the proportions can vary from 1% to 99%. Other embodiments of a mixture of strains are from 25% to 75%. Additional embodiments of a mixture of strains are approximately 50%> for each strain. When a mixture comprises more than two strains, the strains can be present in substantially equal proportions or in different proportions in the mixture.

The DFM may be dosed appropriately.

Suitably dosages of DFM in the feed may be between about l xlO³ CFU/g feed to about l x l O⁹ CFU/g feed, suitably between about lxlO⁴ CFU/g feed to about lxl 0⁸ CFU/g feed, suitably between about 7.5x10⁴ CFU/g feed to about lxlO⁷ CFU/g feed. In one embodiment the DFM is dosed in the feedstuff at more than about l xl ⁽r CFU/g feed, suitably more than about lxlO⁴ CFU/g feed, suitably more than about 7.5xl0⁴ CFU/g feed.

Suitably dosages of DFM in the feed additive composition may be between about l xlO⁵ CFU/g composition to about 1x10 ³ CFU/g composition, suitably between about 1x10 CFU/g composition to about lxl 0¹² CFU/g composition, suitably between about 3.75x 10⁷ CFU/g composition to about lxlO^{1 1} CFU/g composition.

In one embodiment the DFM is dosed in the feed additive composition at more than about lxlO⁵ CFU/g composition, suitably more than about lxl 0⁶ CFU/g composition, suitably more than about 3.75xl0⁷ CFU/g composition. In one embodiment, the DFM is dosed in the feed additive composition at more than about 2 10⁼ CFU/g composition, suitably more than about 2xl 0⁶ CFU/g composition, suitably more than about 3.75x10⁷ CFU/g composition. As used herein the tenn "CFU" means colony forming units and is a measure of viable cells in which a colony represents an aggregate of cells derived from a single progenitor cell.

Xylanase Xylanase is the name given to a class of enzymes which degrade the linear polysaccharide beta-l.,4-xylan into xylose, thus breaking down hemicellulose, one of the major components of plant cell walls.

The xylanase for use in the present invention may be any commercially available xylanase.

Suitably the xylanase may be an endo-l ,4-P-d-xylanase (classified as E.G. 3.2.1 .8) or a 1 ,4 β- xylosidase (classified as E.G. 3.2.1.37).

In one embodiment preferably the xylanase in an endoxylanase, e.g. an endo-l ,4-p-d- xylanase. The classification for an endo-l,4-P-d-xylanase is E.G. 3.2.1.8.

In one embodiment the present invention relates to a DFM in combination with an endoxylanase, e.g. an endo-1 ,4-P-d-xylanase, and another enzyme.

All E.C. enzyme classifications referred to here relate to the classifications provided in Enzyme Nomenclature - Recommendations (1992) of the nomenclature committee of the International Union of Biochemistry and Molecular Biology - ISBN 0-12-226164-3.

Suitably, the xylanase for use in the present invention may be a xylanase from Bacillus, Trichoderma, Thermomyces, Aspergillus and Penicillium.

In one embodiment the xylanase may be the xylanase in Axtra XAP® or Avizyme 1502®, both commercially available products from Danisco A/S. In one preferred embodiment the xylanase for use in the present invention may be one or more of the xylanases in one or more of the commercial products below:

Commercial

Name ® Company Xylanase type Xylanase source

Allzyme PT Alltech endo- 1 ,4-p-xylanase Aspergillus Niger

Andres Pintaluba

Amylofeed S.A endo- 1 ,4-P-xylanase Aspergillus Niger (phoenicis)

Avemix 02 CS Aveve endo- 1 ,4-P-xylanase Trichoderma reesei

AveMix XG 10 Aveve, NL endo- 1 ,4-β-xylanase Trichoderma reesei

Avizyme 1100 Danisco endo- 1 ,4-p-xylanase Trichoderma longibrachiatum

Avizyme 1 1 10 Danisco endo- 1 ,4-P-xylanase Trichoderma longibrachiatum

Avizyme 1202 Danisco endo- 1 ,4-P-xylanase Trichoderma longibrachiatum

Avizyme 1210 Danisco endo- 1 ,4-P-xylanase Trichoderma longibrachiatum

Avizyme 1302 Danisco endo- 1 ,4-P-xylanase Trichoderma longibrachiatum

Avizyme 1500 Danisco endo- 1 ,4-P-xylanase Trichoderma longibrachiatum

Avizyme 1505 Danisco endo- 1 ,4-P-xylanase Trichoderma longibrachiatum

Avizyme SX Danisco endo- 1 ,4-P-xylanase Trichoderma longibrachiatum

Belfeed MP 100 Beldem endo- 1 ,4-p-xylanase Bacillus subtilis

Biofeed Plus DSM endo- 1 ,4-P-xylanase Humicola insolens

Danisco

Glycosidase Danisco Animal

(TPT/L) Nutrition endo- 1 ,4-P-xylanase Trichoderma reesei

Danisco

Xylanase Danisco endo- 1 ,4-P-xylanase Trichoderma reesei

Econase XT ABVista endo- 1 ,4-P-xylanase Trichoderma reesei

Andres Pintaluba

Endofeed® DC S.A. endo- 1 ,4-P-xylanase Aspergillus Niger

Feedlyve AXL Lyven endo- 1 ,4-P-xylanase Trichoderma longibrachiatum

Grindazym GP Danisco endo- 1 ,4-P-xylanase Aspergillus Niger

Grindazym GV Danisco endo- 1 ,4-P-xylanase Aspergillus Niger

Hostazym X Huvepharma endo- 1 ,4-P-xylanase Trichoderma longibrachiatum

Kemzyme Plus

Dry Kemin endo- 1 ,4-P-xylanase Trichoderma viride

Kemzyme Plus

Liquid Kemin endo- 1 ,4-P-xylanase Trichoderma viride

Kemzyme W dry Kemin endo- 1 ,4-P-xylanase Trichoderma viride

Kemzyme W

liquid Kemin endo- 1 ,4-P-xylanase Trichoderma viride

Natugrain BASF endo- 1 ,4-P-xylanase Trichoderma longibrachiatum

Natugrain TS

Plus BASF endo- 1 ,4-P-xylanase Aspergillus Niger

Natugrain Wheat BASF endo-1 ,4-P-xylanase Aspergillus Niger

Natugrain® TS/L BASF endo- 1 ,4-P-xylanase Aspergillus Niger

Trichoderma longibrachiatum

Natuzyme Bioproton endo- 1 ,4-P-xylanase /Trichoderma reesei Porzyme 8100 Danisco endo- 1 ,4-P-xylanase Trichoderma longibrachiatum

Porzyme 8300 Danisco endo-1, 4-P-xylanase Trichoderma longibrachiatum

Porzyme 9102 Danisco endo- 1 ,4-P-xylanase Trichoderma longibrachiatum

Porzyme

9310/Avizyme

1310 Danisco endo- 1 ,4-p-xylanase Trichoderma longibrachiatum

Porzyme tpl OO Danisco endo- 1 ,4-P-xylanase Trichoderma longibrachiatum

Thermomyces lanuginosus gene

expressed in Aspergillus

Ronozyme AX DSM endo- 1 ,4-P-xylanase oryzae

Thermomyces lanuginosus gene

expressed in Aspergillus

Ronozyme WX DSM/Novozymes endo-1 , 4-P-xylanase oryzae

Rovabio Excel Adisseo endo- 1 ,4-P-xylanase Penicillium funiculosum

Roxazyme G2 DSM Novozymes endo- 1 ,4-P-xylanase Trichoderma longibrachiatum

Safizym X Le Saffre endo- 1 ,4-P-xylanase Trichoderma longibrachiatum

Xylanase Lyven endo- 1 ,4-p-xylanase Trichoderma longibrachiatum

Preferably, the xylanase is present in the feedstuff in range of about 500XU/kg to about 16,000XU/kg feed, more preferably about 750XU/k.g feed to about 8000XU/kg feed, and even more preferably about l OOOXU/kg feed to about 4000XU/kg feed

In one embodiment the xylanase is present in the feedstuff at more than about 500XU/kg feed, suitably more than about 600XU/kg feed, suitably more than about 700XU/kg feed, suitably more than about 800XU/kg feed, suitably more than about 900XU/kg feed, suitably more than about l OOOXU/kg feed.

In one embodiment the xylanase is present in the feedstuff at less than about 16,000XU/kg feed, suitably less than about 8000XU/kg feed, suitably less than about 7000XU/kg feed, suitably less than about 6000XU/kg feed, suitably less than about 5000XU/kg feed, suitably less than about 4000XU/kg feed.

Preferably, the xylanase is present in the feed additive composition in range of about l OOXU/g to about 320,000XU/g composition, more preferably about 300XU/g composition to about 160,000XU/g composition, and even more preferably about 500XU/g composition to about 50,000 XU/g composition, and even more preferably about 500XU/g composition to about 40,000 XU/g composition. In one embodiment the xylanase is present in the feed additive composition at more than about l OOXU/g composition, suitably more than about 200XU/g composition, suitably more than about 300XU/g composition, suitably more than about 400XU/g composition, suitably more than about 500XU/g composition.

In one embodiment the xylanase is present in the feed additive composition at less than about 320,000XU/g composition, suitably less than about 160,000XU/g composition, suitably less than about 50,000XU/g composition, suitably less than about 40,000XU/g composition, suitably less than about 30000XU/g composition.

It will be understood that one xylanase unit (XU) is the amount of enzyme that releases 0.5 μηιοΐ of reducing sugar equivalents (as xylose by the Dinitrosalicylic acid (DNS) assay - reducing sugar method) from a oat-spelt-xylan substrate per min at pH 5.3 and 50°C. (Bailey, MJ. Biely, P. and Poutanen, K., Journal of Biotechnology, Volume 23, (3), May 1992, 257- 270).

In one embodiment suitably the enzyme is classified using the E.G. classification above, and the E.G. classification designates an enzyme having that activity when tested in the assay taught herein for determining 1 XU.

Amylase

Amylase is the name given to a class of enzymes capable of hydrolysing starch to shorter-chain oligosaccharides such as maltose. The glucose moiety can then be more easily transferred from maltose to a monoglyceride or glycosylmonoglyceride than from the original starch molecule.

The term amylase includes a-amylases (E.G. 3.2.1.1), G4-foraiing amylases (E.G. 3.2.1.60), β- amylases (E.G. 3.2.1.2) and γ-amylases (E.C. 3.2.1.3). In one embodiment preferably the amylase is an a-amylase. oc-Amylases are classified as (E.C. 3.2.1.1 ). These can include amylases of bacterial or fungal origin, chemically modified or protein engineered mutants are included.

In one embodiment preferably the amylase may be an amylase, e.g. an a-amylase, from Bacillus licheniformis and/or an amylase, e.g. an a-amylase, from Bacillus amyloliquefaciens.

In one embodiment the α-amylase may be the α-amylase in Axtra XAP® or Avizyme 1502®, both commercially available products from Danisco A/S. In another embodiment the amylase may be a pepsin resistant a-amylase, such as a pepsin resistant Trichoderma (such as Trichoderma reesei) alpha amylase. A suitably pepsin resistant α-amylase is taught in UK application number 101 1513.7 (which is incorporated herein by reference) and PCT/IB201 1/053018 (which is incorporated herein by reference). In one embodiment the amylase may be a pepsin resistant α-amylase comprising or consisting of an amino acid sequence:

i) as set forth in SEQ ID No. 1 or SEQ ID No. 3 ;

ii) as set forth in SEQ ID No. 1 or SEQ ID No. 3 except for one or several amino acid additions/insertions, deletions or substitutions;

iii) having at least 85% (preferably, at least 90%, 95%, 97%, 98% or 99%) identity to

SEQ ID No. 1 or at least 70% (preferably, at least 75%, 80%, 85%, 90%, 95%, 97%, 98% or 99%) identity to SEQ ID No. 3;

iv) which is produced by expression of a nucleotide sequence comprising the sequence of SEQ ID No. 2 or SEQ ID No. 4;

v) which is produced by expression of a nucleotide sequence which differs from SEQ

ID No. 2 or SEQ ID No. 4 due to the degeneracy of the genetic code;

vi) which is produced by expression of a nucleotide sequence which differs from SEQ ID No. 2 or SEQ ID No. 4 by one or several nucleotide additions/insertions, deletions or substitutions; or

vii) which is produced by expression of a nucleotide sequence which has at least 70%

(preferably, at least 75%, 80%, 85%, 90%, 95%, 97%, 98% or 99%) identity to SEQ ID No. 2 or SEQ ID No. 4. The pepsin resistant alpha amylase may also be encoded by a nucleotide sequence which hybridises to SEQ ID No. 2 or SEQ ID No. 4 under stringent or highly stringent conditions.

In one preferred embodiment the amylase for use in the present invention may be one or more of the amylases in one or more of the commercial products below:

In one embodiment the amylase may be a maltogenic alpha-amylase from Bacillus (see EP 120 693). This amylase is commercially available under the trade name Novamyl™ ( Novo Nordisk A S, Denmark). Novamyl is described in detail in International Patent Publication WO 91/104669.

Preferably, the amylase is present in the feedstuff in range of about 50AU/kg to about 10,000AU/kg feed, more preferably about 70AU/kg feed to about 7500AU/kg feed, more preferably about 70AU/kg feed to about 5000AU/kg feed and even more preferably about l OOAU/kg feed to about 2000AU kg feed. In one embodiment the amylase is present in the feedstuff at more than about 50AU/kg feed, suitably more than about 60AU/kg feed, suitably more than about 70AU/kg feed, suitably more than about 80AU/kg feed, suitably more than about 90AU/kg feed, suitably more than about 1 OOAU/kg feed.

In one embodiment the amylase is present in the feedstuff at less than about 10,000AU/kg feed, suitably less than about 8000AU/kg feed, suitably less than about 7000AU/kg feed, suitably less than about 5000AU/kg feed, suitably less than about 4000AU/kg feed, suitably less than about 3000AU/kg feed, suitably less than about 2000AU/kg feed.

Preferably, the amylase is present in the feed additive composition in range of about lOAU/kg to about 200,000 AU/g composition, more preferably about 30AU/g composition to about 100,000AU/g composition, and even more preferably about 40AU/g composition to about 50,000 AU/g composition, and even more preferably about 50 AU/g composition to about 20,000 AU/g composition.

In one embodiment the amylase is present in the feed additive composition at more than about 10 AU/g composition, suitably more than about 20AU/g composition, suitably more than about 30 AU/g composition, suitably more than about 40 AU/g composition, suitably more than about 50AU/g composition.

In one embodiment the amylase is present in the feed additive composition at less than about 200,000 AU/g composition, suitably less than about 100,000 AU/g composition, suitably less than about 5O,OO0AU/g composition, suitably less than about 40,000AU/g composition, suitably less than about 30000AU/g composition, suitably less than about 20000AU/g composition.

It will be understood that one amylase unit (AU) is the amount of enzyme that releases 1 mmol of glucosidic linkages from a water insoluble cross-linked starch polymer substrate per min at pH 6.5 and 37°C (this may be referred to herein as the assay for determining 1 AU).

1 TAU (a-amylase activity) is the amount of enzyme required to release (in the presence of excess a-glucosidase) 0.20 μιηοΐ of glucosidic linkages (expressed as -nitrophenol equivalents) from a maltoheptaoside substrate per minute at pH 8.0 and 40 °C . This may be referred to herein as the assay for determining 1 TAU unit.

In one embodiment suitably the enzyme is classified using the E.G. classification above, and the E.G. classification designates an enzyme having that activity when tested in the assay taught herein for determining 1 AU.

Protease

The term protease as used herein is synonymous with peptidase or proteinase.

The protease for use in the present invention may be a subtilisin (E.G. 3.4.21.62) or a bacillolysin (E.G. 3.4.24.28) or an alkaline serine protease (E.G. 3.4.21.x) or a keratinase (E.G. 3.4.X.X). Preferably the protease in accordance with the present invention is a subtilisin.

Suitable proteases include those of animal, vegetable or microbial origin. Chemically modified or protein engineered mutants are also suitable. The protease may be a serine protease or a metalloprotease, e.g., an alkaline microbial protease or a trypsin-like protease. Examples of alkaline proteases are subtilisins, especially those derived from Bacillus sp., e.g., subtilisin Novo, subtilisin Carlsberg, subtilisin 309 (see, e.g., U.S. Patent No. 6,287,841), subtilisin 147, and subtilisin 168 (see, e.g., WO 89/06279). Examples of trypsin-like proteases are trypsin (e.g., of porcine or bovine origin), and Fusarium proteases (see, e.g. , WO 89/06270 and WO 94/25583). Examples of useful proteases also include but are not limited to the variants described in WO 92/19729 and WO 98/201 15.

In one preferred embodiment the protease for use in the present invention may be one or more of the proteases in one or more of the commercial products below:

Commercial product® Company Protease type Protease source

Avizyme 1 100 Danisco A/S Subtilisin Bacillus subtilis

Avizyme 1202 Danisco A/S Subtilisin Bacillus subtilis

Avizyme 1302 Danisco A/S Subtilisin Bacillus subtilis

Avizyme 1500 Danisco A S Subtilisin Bacillus subtilis Avizyme 1505 Danisco A7S Subtilisin Bacillus subtilis

Bacillus

emzyme Plus Dry Kemin Bacillolysin amyloliquefaciens

Bacillus

Kemzyme W dry Kemin Bacillolysin amyloliq uefaciens

Trichoderma longibrachiatum

/Trichoderma

Natuzyme Bioproton Protease reesei

Porzyme 8300 Danisco Subtilisin Bacillus subtilis

Nocardiopsis prasina gene expressed in

Alkaline serine Bacillus

Ronozyme ProAct DSM/Novozymes protease licheniformis

Versazyme/Cibenza Bacillus

DP 100 Novus Keratinase licheniformis

In one embodiment the protease may be a protease from B. subtilis.

In one embodiment the protease may be a Nocardiopsis protease available from Novozymes A/S.

Preferably, the protease is present in the feedstuff in range of about l OOOU/kg to about 20,000PU/kg feed, more preferably about 1500PU/kg feed to about l OOOOPU/kg feed, more preferably about 2000PU/kg feed to about 6000PU/kg feed.

In one embodiment the protease is present in the feedstuff at more than about l OOOPU/kg feed, suitably more than about 1500PU/kg feed, suitably more than about 2000PU/kg feed.

In one embodiment the protease is present in the feedstuff at less than about 20,000PU/kg feed, suitably less than about l OOOOPU/kg feed, suitably less than about 7000PU/kg feed, suitably less than about 6000PU/kg feed.

Preferably, the protease is present in the feed additive composition in range of about 200PU/g to about 400,000PU/g composition, more preferably about 300PU/g composition to about 200,000PU/g composition, and even more preferably about 5000PU/g composition to about 100,000 PU/g composition, and even more preferably about 700PU/g composition to about 70,000 PU/g composition, and even more preferably about lOOOPU/g composition to about 60,000 PU/g composition.

In one embodiment the protease is present in the feed additive composition at more than about 200PU/g composition, suitably more than about 300PU/g composition, suitably more than about 400PU/g composition, suitably more than about 500PU/g composition, suitably more than about 750PU/g composition, suitably more than about lOOOPU/g composition.

In one embodiment the protease is present in the feed additive composition at less than about 400,000PU/g composition, suitably less than about 200,000PU/g composition, suitably less than about 100,000PU/g composition, suitably less than about 80,000PU/g composition, suitably less than about 70000PU/g composition, suitably less than about 60000PU/g composition. It will be understood that one protease unit (PU) is the amount of enzyme that liberates from the substrate (0.6% casein solution) one microgram of phenolic compound (expressed as tyrosine equivalents) in one minute at pH 7.5 (40mM Na₂P0₄ / lactic acid buffer) and 40°C. This may be referred to as the assay for determining 1PU. In one embodiment suitably the enzyme is classified using the E.G. classification above, and the E.C. classification designates an enzyme having that activity when tested in the assay taught herein for determining 1 PU.

Phytase

The phytase for use in the present invention may be classified a 6-phytase (classified as E.C. 3.1.3.26) or a 3-phytase (classified as E.C. 3.1.3.8).

In one embodiment the phytase may be a 6-phytase (E.C. 3.1.3.26). In one preferred embodiment the phytase for use in the present invention may be one or more of the phytases in one or more of the commercial products below: r

Commercial

product® Company Phytase type Phytase source Finase AB Vista 3-phytase Trichoderma reesei

E. coli gene expressed in

Finase EC ABVista 6-phytase Trichoderma reesei

Natuphos BASF 3-phytase Aspergillus Niger

Trichoderma

phytase (type longibrachiaium

Natuzyme Bioproton not specified) /Trichoderma reesei

E. coli gene expressed in

OPTIPHOS® Huvcpharma AD 6-phytase Pichia pastoris

A consensus gene expressed

Phytase sp l 002 DSM 3-phytase in Hansenula polymorpha

E. coli gene expressed in

Phyzyme XP Danisco 6-phytase Schizosaccahomyces pombe

E. coli gene expressed in

Quantum 2500D, Pichia pastoris or 5000L ABVista 6-phytase Trichoderma

Citrohacter braakii gene

Ronozymc Hi-Phos expressed in Aspergillus (M/L) DSM/Novozymes 6-phytase oryzae

Peniphora lycii gene expressed in Aspergillus

Ronozyme NP DSM Novozymes 6-phytase oryzae

Peniphora lycii gene expressed in Aspergillus

Ronozyme P DSM/Novozymes 6-phytase oryzae

Rovabio PHY Adisseo 3-phytase Penicillium funiculosum

The term consensus gene as used herein means that the DNA vector used to transform the organism contains a synthetic phytase gene based on a consensus sequence, a URA gene from the non-pathogenic yeast Saccharomyces cerevisiae and the origin of replication of the Escherichia coli plasmid pBR322.

In one embodiment the phytase is a Citrohacter phytase derived from e.g. Citrobacter freundii, preferably C. freundii NCIMB 41247 and variants thereof e.g. as disclosed in WO2006/038062 (incorporated herein by reference) and WO2006/038128 (incorporated herein by reference), Citrobacter braakii YH-15 as disclosed in WO 2004/085638, Citrohacter braakii ATCC 51 1 13 as disclosed in WO2006/037328 (incorporated herein by reference), as well as variants thereof e.g. as disclosed in WO2007/1 12739 (incorporated herein by reference) and WO201 1/1 17396 (incorporated herein by reference), Citrobacter amalonaticus, preferably Citrobacter amalonaticus ATCC 25405 or Citrobacter amalonaticus ATCC 25407 as disclosed in WO2006037327 (incorporated herein by reference), Citrobacter gillenii, preferably Citrobacter gillenii DSM 13694 as disclosed in 4

31

WO2006037327 (incorporated herein by reference), or Citrobacter intermedins, Citrobacter koseri, Citrobacter murliniae, Citrobacter rodentium, Citrobacter sedlakii, Citrobacter werbnanii, Citrobacter youngae, Citrobacter species polypeptides or variants thereof. In one embodiment the phytase may be a phytase from Citrobacter, e.g. from Citrobacter freundii, such as the phytase enzyme(s) taught in WO2006/038128, which reference is incorporated herein by reference.

In preferred embodiments, the phytase is preferably E. coli phytase marketed under the name Phyzyme XP™ by Danisco A/S.

Alternatively the phytase may be a Buttiauxella phytase, e.g. a Buttiauxella agrestis phytase, for example, the phytase enzymes taught in WO 2006/043178, WO 2008/097619, WO2009/129489, WO2008/092901 , PCT/US2009/4101 1 or PCT/IB2010/051804, all of which are incorporated herein by reference.

In one embodiment the phytase may be a phytase from Hafnia, e.g. from Hafnia alvei, such as the phytase enzyme(s) taught in US2008263688, which reference is incorporated herein by reference.

In one embodiment the phytase may be a phytase from Aspergillus, e.g. from Apergillus orzyae.

In one embodiment the phytase may be a phytase from Penicillium, e.g. from Penicillium funiculosum.

Preferably, the phytase is present in the feedstuff in range of about 200FTU/kg to about l OOOFTU/kg feed, more preferably about 300FTU/kg feed to about 750FTU/kg feed, more preferably about 400FTU/kg feed to about 500FTU/kg feed.

In one embodiment the phytase is present in the feedstuff at more than about 200FTU/kg feed, suitably more than about 300FTU/kg feed, suitably more than about 400FTU/kg feed. In one embodiment the phytase is present in the feedstuff at less than about lOOOFTU/kg feed, suitably less than about 750FTU/kg feed.

Preferably, the phytase is present in the feed additive composition in range of about 40FTU/g to about 40,000FTU/g composition, more preferably about 80FTU/g composition to about 20,000FTU/g composition, and even more preferably about lOOFTU/g composition to about 10,000FTU/g composition, and even more preferably about 200FTU/g composition to about 10,000FTU/g composition. In one embodiment the phytase is present in the feed additive composition at more than about 40FTU/g composition, suitably more than about 60FTU/g composition, suitably more than about lOOFTU/g composition, suitably more than about 150FTU/g composition, suitably more than about 200FTU/g composition. In one embodiment the phytase is present in the feed additive composition at less than about 40,000FTU/g composition, suitably less than about 20,000FTU/g composition, suitably less than about 15,000FTU/g composition, suitably less than about 10,000FTU/g composition.

It will be understood that as used herein 1 FTU (phytase unit) is defined as the amount of enzyme required to release 1 μηιοΐ of inorganic orthophosphate from a substrate in one minute under the reaction conditions defined in the ISO 2009 phytase assay - A standard assay for determining phytase activity and 1 FTU can be found at International Standard ISO/DIS 30024: 1-17, 2009. In one embodiment suitably the enzyme is classified using the E.G. classification above, and the E.G. classification designates an enzyme having that activity when tested in the assay taught herein for determining 1 FTU.

Advantages

The interaction of DFMs with enzymes is complicated and without wishing to be bound by theory, it is very surprising that we can see an improvement in the subject's resistance to necrotic enteritis, e.g. that we see a reduction in lesion scores for instance. Prior to the present invention the combination of DFMs and enzymes (e.g. as taught herein) had not been taught for this specific purpose.

One advantage of the present invention is that the feed additive composition according to the present invention can avoid the negative effects of necrotic enteritis or can be used for improving the subject's resistance to necrotic enteritis.

Without wishing to be bound by theory, phytase catalyses the sequential hydrolysis of phytate, a principal storage form of phosphorus in cereals and legumes, to less phosphorylated myo-inositol derivatives with concomitant release of inorganic phosphate. Hydrolysis of phytate causes a reduction of endogenous losses of amino acids to the intestinal lumen. A reduction of endogenous amino acid losses in the intestine reduces the availability of nitrogen for bacterial growth, which helps the activity of DFMs on inhibition of C. perfringens and other pathogenic bacteria.

Without wishing to be bound in theory proteases cause non-specific hydrolysis of dietary protein yielding a variety of polypeptides in the intestinal lumen. Animals finalise protein hydrolysis and absorb such amino acids. However, in the case of enteric pathogenic challenges, pathogenic bacteria may take advantage of higher peptide availability in the lumen of jejunum and ileum. DFMs inhibit the growth of entero-pathogens by for example competing for N sources, as well as by direct inhibition.

In addition, xylanase degrades the linear polysaccharide beta-l,4-xylan into xylose.. Without wishing to be bound by theory, the inventors herein have shown that the increased energy digestibility with the combination of DFMs and enzymes is not explained by starch, fat or protein, therefore it must be explained by non-starch polysaccharides.

Amylase activity hydrolyses alpha-bonds of large alpha-linked polysaccharides such as starch yielding dextrins and oligosaccharides, which are mainly absorbed in the small intestine after hydrolysis to maltose and glucose in the gut wall. Surprisingly, rapid starch hydrolysis in the foregut and greater absorption of glucose in the duodenum deprives pathogenic bacteria from an important energy source (glucose) in the jejunum and ileum, which improves the DFM activity because of a competitive advantage against pathogens that cannot use pentoses as efficiently.

In combination the four enzymes and DFMs surprisingly provide a significant improvement on the pathogen reduction and/or resistance to necrotic enteritis compared with other DFM and enzyme combinations and/or DFMs alone and/or enzyme(s) alone.

The specific combination of DFMs and the enzymes taught herein may advantageously lead to reduced mucin secretion. Without wishing to be bound by theory this reduced mucin secretion may result in a reduction of endogenous amino acid losses, and/or may be responsible for improved performance.

The specific combination of DFMs and the enzymes taught herein may advantageously reduce inflammation in the ileum. This can be seen by the downregulation of IFR-g expression in the ileum. The inventors have shown that modulation of immune response may improve performance.

Formulation of the DFM with the enzymes

The DFM and the enzymes may be formulated in any suitable way to ensure that the formulation comprises viable DFMs and active enzymes.

In one embodiment the DFM and enzymes may be formulated as a liquid, a dry powder or a granule. The dry powder or granules may be prepared by means known to those skilled in the art, such as, in top-spray fluid bed coater, in a buttom spray Wurster or by drum granulation (e.g. High sheer granulation), extrusion, pan coating or in a microingredients mixer.

For some embodiments the DFM and/or the enzyme(s) may be coated, for example encapsulated. Suitably the DFM and enzymes may be formulated within the same coating or encapsulated within the same capsule. Alternatively one or two or three or four of the enzymes may be formulated within the same coating or encapsulated within the same capsule and the DFM could be formulated in a coating separate to the one or more or all of the enzymes. In some embodiments, such as where the DFM is capable of producing cndosporcs, the DFM may be provided without any coating. In such circumstances, the DFM endospores may be simply admixed with one or two or three or four enzymes. In the latter case, the enzymes may be coated, e.g. encapsulated, for instance one or more or all of the enzymes may be coated, e.g. encapsulated. The enzymes may be encapsulated as mixtures (i.e. comprising one or more, two or more, three or more or all) of enzymes or they may be encapsulated separately, e.g. as single enzymes. In one preferred embodiment all four enzymes may be coated, e.g. encapsulated, together. In one embodiment the coating protects the enzymes from heat and may be considered a thermoprotectant.

In one embodiment the feed additive composition is formulated to a dry powder or granules as described in WO2007/044968 (referred to as TPT granules) or WOl 997/016076 or WO 1992/012645 (each of which is incorporated herein by reference).

In one embodiment the feed additive composition may be formulated to a granule for feed compositions comprising: a core; an active agent; and at least one coating, the active agent of the granule retaining at least 50% activity, at least 60% activity, at least 70% activity, at least 80%) activity after conditions selected from one or more of a) a feed pelleting process, b) a steam-heated feed pretreatment process, c) storage, d) storage as an ingredient in an unpelleted mixture, and e) storage as an ingredient in a feed base mix or a feed premix comprising at least one compound selected from trace minerals, organic acids, reducing sugars, vitamins, choline chloride, and compounds which result in an acidic or a basic feed base mix or feed premix.

With regard to the granule at least one coating may comprise a moisture hydrating material that constitutes at least 55% w/w of the granule; and/or at least one coating may comprise two coatings. The two coatings may be a moisture hydrating coating and a moisture barrier coating. In some embodiments, the moisture hydrating coating may be between 25%o and 60%> w/w of the granule and the moisture barrier coating may be between 2%> and 15% w/w of the granule. The moisture hydrating coating may be selected from inorganic salts, sucrose, starch, and rnaltodextrin and the moisture barrier coating may be selected from polymers, gums, whey and starch.

The granule may be produced using a feed pelleting process and the feed pretreatment process may be conducted between 70°C and 95°C for up to several minutes, such as between 85°C and 95°C.

In one embodiment the feed additive composition may be formulated to a granule for animal feed comprising: a core; an active agent, the active agent of the granule retaining at least 80% activity after storage and after a steam-heated pelleting process where the granule is an ingredient; a moisture barrier coating; and a moisture hydrating coating that is at least 25% w/w of the granule, the granule having a water activity of less than 0.5 prior to the steam- heated pelleting process. The granule may have a moisture barrier coating selected from polymers and gums and the moisture hydrating material may be an inorganic salt. The moisture hydrating coating may be between 25% and 45% w/w of the granule and the moisture barrier coating may be between 2% and ] 0% w/w of the granule. The granule may be produced using a steam-heated pelleting process which may be conducted between 85°C and 95°C for up to several minutes.

In some embodiments the DFM (e.g. DFM endospores for example) may be diluted using a diluent, such as starch powder, lime stone or the like.

In one embodiment, the composition is in a liquid formulation suitable for consumption preferably such liquid consumption contains one or more of the following: a buffer, salt, sorbitol and/or glycerol. In another embodiment the feed additive composition may be formulated by applying, e.g. spraying, the enzyme(s) onto a carrier substrate, such as ground wheat for example. In one embodiment the feed additive composition according to the present invention may be formulated as a premix. By way of example only the premix may comprise one or more feed components, such as one or more minerals and/or one or more vitamins. In one embodiment the DFM and/or enzymes for use in the present invention are formulated with at least one physiologically acceptable earner selected from at least one of maltodextrin, limestone (calcium carbonate), cyclodcxtrin. wheat or a wheat component, sucrose, starch, Na₂S0₄, Talc, PVA, sorbitol, benzoate, sorbiate, glycerol, sucrose, propylene glycol, 1 ,3- propane diol, glucose, parabens, sodium chloride, citrate, acetate, phosphate, calcium, metabisulfite, formate and mixtures thereof.

Packaging

In one embodiment the feed additive composition and/or premix and/or feed or feedstuff according to the present invention is packaged.

In one preferred embodiment the feed additive composition and/or premix and/or feed or feedstuff is packaged in a bag, such as a paper bag.

In an alternative embodiment the feed additive composition and/or premix and/or feed or feedstuff may be sealed in a container. Any suitable container may be used.

Feed

The feed additive composition of the present invention may be used as - or in the preparation of - a feed.

The term "feed" is used synonymously herein with "feedstuff.

The feed may be in the form of a solution or as a solid - depending on the use and/or the mode of application and/or the mode of administration.

When used as - or in the preparation of - a feed -- such as functional feed - the composition of the present invention may be used in conjunction with one or more of: a nutritionally acceptable carrier, a nutritionally acceptable diluent, a nutritionally acceptable excipient, a nutritionally acceptable adjuvant, a nutritionally active ingredient.

In a preferred embodiment the feed additive composition of the present invention is admixed with a feed component to form a feedstuff.

The term "feed component" as used herein means all or part of the feedstuff. Part of the feedstuff may mean one constituent of the feedstuff or more than one constituent of the feedstuff, e.g. 2 or 3 or 4. In one embodiment the term "feed component" encompasses a premix or premix constituents.

Preferably the feed may be a fodder, or a premix thereof, a compound feed, or a premix thereof. In one embodiment the feed additive composition according to the present invention may be admixed with a compound feed, a compound feed component or to a premix of a compound feed or to a fodder, a fodder component, or a premix of a fodder.

The term fodder as used herein means any food which is provided to an animal (rather than the animal having to forage for it themselves). Fodder encompasses plants that have been cut.

The term fodder includes hay, straw, silage, compressed and pelleted feeds, oils and mixed rations, and also sprouted grains and legumes.

Fodder may be obtained from one or more of the plants selected from: alfalfa (lucerne), barley, birdsfoot trefoil, brassicas, Chau moellier, kale, rapeseed (canola), rutabaga (swede), turnip, clover, alsike clover, red clover, subterranean clover, white clover, grass, false oat grass, fescue, Bermuda grass, brome, heath grass, meadow grasses (from naturally mixed grassland swards, orchard grass, rye grass, Timothy-grass, corn (maize), millet, oats, sorghum, soybeans, trees (pollard tree shoots for tree-hay), wheat, and legumes.

The term "compound feed" means a commercial feed in the form of a meal, a pellet, nuts, cake or a crumble. Compound feeds may be blended from various raw materials and additives. These blends are formulated according to the specific requirements of the target animal.

Compound feeds can be complete feeds that provide all the daily required nutrients, concentrates that provide a part of the ration (protein, energy) or supplements that only provide additional micronutrients, such as minerals and vitamins.

The main ingredients used in compound feed are the feed grains, which include com, soybeans, sorghum, oats, and barley.

Suitably a premix as referred to herein may be a composition composed of microingredients such as vitamins, minerals, chemical preservatives, antibiotics, fermentation products, and other essential ingredients. Premixes are usually compositions suitable for blending into commercial rations.

Any feedstuff of the present invention may comprise one or more feed materials selected from the group comprising a) cereals, such as small grains (e.g., wheat, barley, rye, oats and combinations thereof) and/or large grains such as maize or sorghum; b) by products from cereals, such as com gluten meal, Distillers Dried Grain Solubles (DDGS), wheat bran, wheat middlings, wheat shorts, rice bran, rice hulls, oat hulls, palm kernel, and citrus pulp; c) protein obtained from sources such as soya, sunflower, peanut, lupin, peas, fava beans, cotton, canola, fish meal, dried plasma protein, meat and bone meal, potato protein, whey, copra, sesame; d) oils and fats obtained from vegetable and animal sources; e) minerals and vitamins.

A feedstuff of the present invention may contain at least 30%, at least 40%, at least 50% or at least 60% by weight com and soybean meal or com and full fat soy, or wheat meal or sunflower meal.

In addition or in the alternative, a feedstuff of the present invention may comprise at least one high fibre feed material and/or at least one by-product of the at least one high fibre feed material to provide a high fibre feedstuff. Examples of high fibre feed materials include: wheat, barley, rye, oats, by products from cereals, such as com gluten meal, Distillers Dried Grain Solubles (DDGS), wheat bran, wheat middlings, wheat shorts, rice bran, rice hulls, oat hulls, palm kernel, and citrus pulp. Some protein sources may also be regarded as high fibre: protein obtained from sources such as sunflower, lupin, fava beans and cotton.

In the present invention the feed may be one or more of the following: a compound feed and premix, including pellets, nuts or (cattle) cake; a crop or crop residue: com, soybeans, sorghum, oats, barley, com stover, copra, straw, chaff, sugar beet waste; fish meal; freshly cut grass and other forage plants; meat and bone meal; molasses; oil cake and press cake; oligosaccharides; conserved forage plants: hay and silage; seaweed; seeds and grains, either whole or prepared by crushing, milling etc.; sprouted grains and legumes; yeast extract.

The term feed in the present invention also encompasses in some embodiments pet food. A pet food is plant or animal material intended for consumption by pets, such as dog food or cat food. Pet food, such as dog and cat food, may be either in a dry form, such as kibble for dogs, or wet canned form. Cat food may contain the amino acid taurine.

The term feed in the present invention also encompasses in some embodiments fish food. A fish food normally contains macro nutrients, trace elements and vitamins necessary to keep captive fish in good health. Fish food may be in the form of a flake, pellet or tablet. Pelleted forms, some of which sink rapidly, are often used for larger fish or bottom feeding species. Some fish foods also contain additives, such as beta carotene or sex hormones, to artificially enhance the color of ornamental fish.

The term feed in the present invention also encompasses in some embodiment bird food. Bird food includes food that is used both in birdfeeders and to feed pet birds. Typically bird food comprises of a variety of seeds, but may also encompass suet (beef or mutton fat).

As used herein the term "contacted" refers to the indirect or direct application of the composition of the present invention to the product (e.g. the feed). Examples of the application methods which may be used, include, but are not limited to, treating the product in a material comprising the feed additive composition, direct application by mixing the feed additive composition with the product, spraying the feed additive composition onto the product surface or dipping the product into a preparation of the feed additive composition. In one embodiment the feed additive composition of the present invention is preferably admixed with the product (e.g. feedstuff). Alternatively, the feed additive composition may be included in the emulsion or raw ingredients of a feedstuff. For some applications, it is important that the composition is made available on or to the surface of a product to be affected/treated. This allows the composition to impart one r more of the following favourable characteristics: performance benefits.

The feed additive compositions of the present invention may be applied to intersperse, coat and/or impregnate a product (e.g. feedstuff or raw ingredients of a feedstuff) with a controlled amount of DFM and enzymes.

The DFM and enzymes may be used simultaneously (e.g. when they are in admixture together or even when they are delivered by different routes) or sequentially (e.g. they may be delivered by different routes). In one embodiment preferably the DFM and enzymes are applied simultaneously. Preferably the DFM and enzymes are admixed prior to being delivered to a feedstuff or to a raw ingredient of a feedstuff.

The DFM in feed additive compositions according to the present invention - can be added in suitable concentrations - such as for example in concentrations in the final feed product which offer a daily dose of between about 2x10³ CFU to about 2x10^{1 1} CFU, suitably between about 2xl 0⁶ to about lxlO¹⁰, suitably between about 3.75xl0⁷ CFU to about l lO¹⁰ CFU.

Preferably, the feed additive composition of the present invention will be thermally stable to heat treatment up to about 70 °C; up to about 85°C; or up to about 95°C. The heat treatment may be performed for up to about 1 minute; up to about 5 minutes; up to about 10 minutes; up to about 30 minutes; up to about 60 minutes. The term thermally stable means that at least about 75% of the enzyme components and/or DFM that were present/active in the additive before heating to the specified temperature are still present/active after it cools to room temperature. Preferably, at least about 80% of the enzyme components and/or DFM that were present and active in the additive before heating to the specified temperature are still present and active after it cools to room temperature. In a particularly preferred embodiment the feed additive composition is homogenized to produce a powder.

In an alternative preferred embodiment, the feed additive composition is formulated to granules as described in WO2007/044968 (referred to as TPT granules) incorporated herein by reference.

In another preferred embodiment when the feed additive composition is formulated into granules the granules comprise a hydrated barrier salt coated over the protein core. The advantage of such salt coating is improved thermo-tolerance, improved storage stability and protection against other feed additives otherwise having adverse effect on the enzyme and/or DFM.

Preferably, the salt used for the salt coating has a water activity greater than 0.25 or constant humidity greater than 60 % at 20 °C.

Preferably, the salt coating comprises aNa₂S0₄.

The method of preparing a feed additive composition may also comprise the further step of pelleting the powder. The powder may be mixed with other components known in the art. The powder, or mixture comprising the powder, may be forced through a die and the resulting strands are cut into suitable pellets of variable length.

Optionally, the pelleting step may include a steam treatment, or conditioning stage, prior to formation of the pellets. The mixture comprising the powder may be placed in a conditioner, e.g. a mixer with steam injection. The mixture is heated in the conditioner up to a specified temperature, such as from 60-100°C, typical temperatures would be 70°C, 80°C, 85°C, 90°C or 95°C. The residence time can be variable from seconds to minutes and even hours. Such as 5 seconds, 10 seconds, 15 seconds, 30 seconds, 1 minutes 2 minutes., 5 minutes, 10 minutes, 15 minutes, 30 minutes and 1 hour.

It will be understood that the feed additive composition of the present invention is suitable for addition to any appropriate feed material. As used herein, the term feed material refers to the basic feed material to be consumed by an animal. It will be further understood that this may comprise, for example, at least one or more unprocessed grains, and/or processed plant and/or animal material such as soybean meal or bone meal.

As used herein, the term "feedstuff refers to a feed material to which one or more feed additive compositions have been added. It will be understood by the skilled person that different animals require different feedstuffs, and even the same animal may require different feedstuffs, depending upon the purpose for which the animal is reared.

Preferably, the feedstuff may comprise feed materials comprising maize or corn, wheat, barley, triticale, rye, rice, tapioca, sorghum, and/ or any of the by-products, as well as protein rich components like soybean mean, rape seed meal, canola meal, cotton seed meal, sunflower seed mean, animal-by-product meals and mixtures thereof. More preferably, the feedstuff may comprise animal fats and / or vegetable oils. Optionally, the feedstuff may also contain additional minerals such as, for example, calcium and/or additional vitamins.

Preferably, the feedstuff is a corn soybean meal mix. In one embodiment, preferably the feed is not pet food.

In another aspect there is provided a method for producing a feedstuff. Feedstuff is typically produced in feed mills in which raw materials are first ground to a suitable particle size and then mixed with appropriate additives. The feedstuff may then be produced as a mash or pellets; the later typically involves a method by which the temperature is raised to a target level and men the feed is passed through a die to produce pellets of a particular size. The pellets are allowed to cool. Subsequently liquid additives such as fat and enzyme may be added. Production of feedstuff may also involve an additional step that includes extrusion or expansion prior to pelleting - in particular by suitable techniques that may include at least the use of steam.

The feedstuff may be a feedstuff for a monogastnc animal, such as poultry (for example, broiler, layer, broiler breeders, turkey, duck, geese, water fowl), swine (all age categories), a pet (for example dogs, cats) or fish, preferably the feedstuff is for poultry.

In one embodiment the feedstuff is not for a layer. By way of example only a feedstuff for chickens, e.g. broiler chickens may be comprises of one or more of the ingredients listed in the table below, for example in the %ages given in the table below:

By way of example only the diet specification for chickens, such as broiler chickens, may be as set out in the Table below:

By way of example only a feedstuff laying hens may be comprises of one or more ingredients listed in the table below, for example in the %ages given in the table below:

By way of example only the diet specification for laying hens may be as set out in the Table below:

By way of example only a feedstuff for turkeys may be comprises of one or more ingredients listed in the table below, for example in the %ages given in the table below:

Ingredient Phase 1 (%) Phase 2 (%) Phase 3 (%) Phase 4 (%)

Wheat 33.6 42.3 52.4 61.6

Maize DDGS 7.0 7.0 7.0 7.0

Soyabean Meal 48%CP 44.6 36.6 27.2 19.2

Rapeseed Meal 4.0 4.0 4.0 4.0

Soyabean Oil 4.4 4.2 3.9 3.6

L-Lysine HCl 0.5 0.5 0.4 0.4

DL-methionine 0.4 0.4 0.3 0.2 L-threonine 0.2 0.2 0.1 0.1

Salt 0.3 0.3 0.3 0.3

Limestone 1.0 1.1 1.1 1.0

Dicalcium Phosphate 3.5 3.0 2.7 2.0

Poultry Vitamins and Micro-

0.4 0.4 0.4 0.4 minerals

By way of example only the diet specification for turkeys may be as set out in the Table below:

By way of example only a feedstuff for piglets may be comprises of one or more ingredients listed in the table below, for example in the %ages given in the table below:

By way of example only the diet specification for piglets may be as set out in the Table below:

By way of example only a feedstuff for grower/finisher pigs may be comprises of one or more of the ingredients listed in the table below, for example in the %ages given in the table below:

Forms The feed additive composition of the present invention and other components and/or the feedstuff comprising same may be vised in any suitable form.

The feed additive composition of the present invention may be used in the form of solid or liquid preparations or alternatives thereof. Examples of solid preparations include powders, pastes, boluses, capsules, pellets, tablets, dusts, and granules which may be wettable, spray- dried or freeze-dried. Examples of liquid preparations include, but are not limited to, aqueous, organic or aqueous-organic solutions, suspensions and emulsions. In some applications, DFM or feed additive compositions of the present invention may be mixed with feed or administered in the drinking water. In one embodiment the dosage range for inclusion into water is about 1x10 3 CFU/animal/day to about 1x1010 CFU/animal/day, and more preferably about lxlO⁷ CFU/animal/day. Suitable examples of forms include one or more of: powders, pastes, boluses, pellets, tablets, pills, capsules, ovules, solutions or suspensions, which may contain flavouring or colouring agents, for immediate-, delayed-, modified-, sustained-, pulsed- or controlled-release applications. By way of example, if the composition of the present invention is used in a solid, e.g. pelleted form, it may also contain one or more of: excipients such as microcrystalline cellulose, lactose, sodium citrate, calcium carbonate, dibasic calcium phosphate and glycine; disintegrants such as starch (preferably corn, potato or tapioca starch), sodium starch glycollate, croscarmellose sodium and certain complex silicates; granulation binders such as polyvinylpyrrolidone, hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC), sucrose, gelatin and acacia; lubricating agents such as magnesium stearate, stearic acid, glyceryl behenate and talc may be included.

Examples of nutritionally acceptable carriers for use in preparing the forms include, for example, water, salt solutions, alcohol, silicone, waxes, petroleum jelly, vegetable oils, polyethylene glycols, propylene glycol, liposomes, sugars, gelatin, lactose, amylose, magnesium stearate, talc, surfactants, silicic acid, viscous paraffin, perfume oil, fatty acid monoglycerides and diglycerides, petroethral fatty acid esters, hydroxymethyl-cellulose, polyvinylpyrrolidone, and the like.

Preferred excipients for the forms include lactose, starch, a cellulose, milk sugar or high molecular weight polyethylene glycols.

For aqueous suspensions and/or elixirs, the composition of the present invention may be combined with various sweetening or flavouring agents, colouring matter or dyes, with emulsifying and/or suspending agents and with diluents such as water, propylene glycol and glycerin, and combinations thereof.

Non-hydroscopic whey is often used as a carrier for DFMs (particularly bacterial DFMs) and is a good medium to initiate growth. Bacterial DFM containing pastes may be fomiulated with vegetable oil and inert gelling ingredients.

Fungal products may be fomiulated with grain by-products as carriers. In one embodiment preferably the feed additive composition according to the present invention is not in the form of a microparticle system, such as the microparticle system taught in WO2005/123034.

Dosing

The DFM and/or feed additive composition according to the present invention may be designed for one-time dosing or may be designed for feeding on a daily basis.

The optimum amount of the composition (and each component therein) to be used in the combination of the present invention will depend on the product to be treated and/or the method of contacting the product with the composition and/or the intended use for the same.

The amount of DFM and enzymes used in the compositions should be a sufficient amount to be effective and to remain sufficiently effective in improving the performance of the animal fed feed products containing said composition. This length of time for effectiveness should extend up to at least the time of utilisation of the product (e.g. feed additive composition or feed containing same). The ratio of DFM to each enzyme in the feed can be in the ranges given below:

DFM:phytase (CFU/FTU): In range from 5.0x10²CFU DFM: I FTU enzyme to 5.0x10⁹ CFU : 1FTU enzyme; preferably in the range from 7.5x 10⁴CFU DFM: I FTU enzyme to 2.5x 10⁷ CFU : IFTU enzyme.

DFM: xylanase (CFU/XU): In range from 6.25x 10'CFU DFM: I XU enzyme to 2.0x10⁹ CFU : 1 XU enzyme; preferably in the range from 1.88xl0⁴CFU DFM: IXU enzyme to l .Oxl O⁷ CF : IXU enzyme. DFM: amylase (CFU/AU): In range from 1.0xl0²CFU DFM: 1AU enzyme to 2.0xl0¹⁰ CFU : 1AU enzyme; preferably in the range from 3.7x10⁴CFU DFM: 1 AU enzyme to 1 .0x10^s CFU : 1AU enzyme.

DFM: protease (CFU/PU): In range from 5.0x 1 'CFU DFM: 1PU enzyme to l .Ox l O⁹ CFU : 1PU enzyme; preferably in the range from 1.25x l0⁴CFU DFM: 1PU enzyme to 5.0xl0⁶ CFU : 1PU enzyme.

In one embodiment preferably the feedstuff comprises the following:

a protease at at least 4000PU/kg of feed;

a xylanase at at least 1 OOOXU/kg to 2000XU/kg of feed (e.g. Avizyme at lOOOXU/kg of feed or Axtra XAP at at least 2000XU/kg of feed);

an amylase; at least 1800AU/kg or 200TAU/kg of feed (e.g. Avizyme at 1800AU/kg or Axtra XAP at at least 200 TAU/kg of feed);

a phytase at at least 500FTU/kg of feed; and

Envivo Pro (DFM) at at least 75,000 CFU/g to 150,000 CFU/g of feed.

In one embodiment preferably the feedstuff comprises the following:

a protease at 4000PU/kg of feed; a xylanase at 1 OOOXU/kg to 2000XU/kg of feed (e.g. Avizyme at lOOOXU/kg of feed or Axtra XAP at 2000XU/kg of feed);

an amylase; 1800AU/kg or 200TAU/kg of feed (e.g. Avizyme at 1800AU/kg or Axtra XAP at 200 TAU/kg of feed);

a phytase at 500FTU kg of feed; and

Envivo Pro (DFM) at 75,000 CFU/g to 150,000 CFU/g of feed.

In one embodiment preferably the feedstuff comprises the following:

a protease at 5000PU/kg of feed;

a xylanase at 1250XU/kg to 2500XU/kg of feed (e.g. Avizyme at 1 OOOXLJ/kg of feed or Axtra XAP at 2500XU/kg of feed);

an amylase; 2250AU/kg or 250TAU/kg of feed (e.g. Avizyme at 1800AU/kg or Axtra XAP at 250 TAU kg of feed);

a phytase at 625FTU/kg of feed; and

Envivo Pro (DFM) at 75,000 CFU/g to 150,000 CFU/g of feed.

In another embodiment the feedstuff comprises the following:

a protease at 2000PU/kg of feed;

a xylanase at 500XU/kg to lOOOXU/kg of feed (e.g. Avizyme at 500XU/kg of feed or Axtra XAP at 1 OOOXU/kg of feed);

an amylase; 900AU/kg or l OOTAU/kg of feed (e.g. Avizyme at 900AU/kg or Axtra XAP at

100 TAU/kg of feed);

a phytase at 500FTU/kg of feed; and

Envivo Pro (DFM) at 37,500 CFU/g to 75,000 CFU/g of feed.

In a preferred embodiment the feed additive composition comprises sufficient enzyme and DFMs to dose the feedstuff as follows:

a protease at 4000PU/kg of feed;

a xylanase at 1 OOOXU/kg to 2000XU/kg of feed (e.g. Avizyme at 1 OOOXU/kg of feed or Axtra XAP at 2000XU/kg of feed);

an amylase; 1800AU/kg or 200TAU/kg of feed (e.g. Avizyme at 1800AU/kg or Axtra XAP at

200 TAU/kg of feed);

a phytase at 500FTU/kg of feed; and Envivo Pro (DFM) at 75,000 CFU/g to 150,000 CFU/g of feed.

a protease at 2000PU/kg of feed;

a xylanase at 500XU/kg to 1 OOOXU/kg of feed (e.g. Avizyme at 500XU/kg of feed or Axtra XAP at 1 OOOXU/kg of feed);

an amylase; 900AU/kg or lOOTAU/kg of feed (e.g. Avizyme at 900AU/kg or Axtra XAP at 100 TAU/kg of feed);

a phytase at 500FTU/kg of feed; and

Envivo Pro (DFM) at 37,500 CFU/g to 75,000 CFU/g of feed.

Combination with Other Components

The DFM and enzyme(s) for use in the present invention may be used in combination with other components. Thus, the present invention also relates to combinations. The DFM in combination with a protease, xylanase, amylase and phytase may be refen-ed to herein as "the feed additive composition of the present invention".

The combination of the present invention comprises the feed additive composition of the present invention (or one or more of the constituents thereof) and another component which is suitable for animal consumption and is capable of providing a medical or physiological benefit to the consumer.

In one embodiment preferably the "another component" is not a further enzyme or a further DFM.

The components may be prebiotics. Prebiotics are typically non-digestible carbohydrate (oligo- or polysaccharides) or a sugar alcohol which is not degraded or absorbed in the upper digestive tract. Known prebiotics used in commercial products and useful in accordance with the present invention include inulin (fructo-oligosaccharide, or FOS) and transgalacto- oligosaccharides (GOS or TOS). Suitable prebiotics include palatinoseoligosaccharide, soybean oligosaccharide, alginate, xanthan, pectin, locust bean gum (LBG), inulin, guar gum, galacto-oligosaccharide (GOS), fructo-oligosaccharide (FOS), non-degradable starch, lactosaccharose, lactulose, lactitol, maltitol, maltodextrin, polydextrose (i.e. Litesse®), lactitol. lactosucrose, soybean oligosaccharides, palatinose. isomalto-oligosaccharides, gluco- oligosaccharides and xylo-oligosaccharides, pectin fragments, dietary fibres, mannan- oli go saccharides.

Dietary fibres may include non-starch polysaccharides, such as arabinoxylans. cellulose and many other plant components, such as resistant dextrins. inulin, lignin, waxes, chitins, pectins, beta-glucans and oligosaccharides. In one embodiment the present invention relates to the combination of the feed additive composition (or one or more of the constituents thereof) according to the present invention with a prebiotic. In another embodiment the present invention relates to a feed additive composition comprising (or consisting essentially of or consisting of) a DFM in combination with a xylanase, an amylase, a phytase, a protease and a prebiotic.

The prebiotic may be administered simultaneously with (e.g. in admixture together with or delivered simultaneously by the same or different routes) or sequentially to (e.g. by the same or different routes) the feed additive composition (or constituents thereof) according to the present invention.

Other components of the combinations of the present invention include polydextrose, such as Litesse®, and/or a maltodextrin and/or lactitol. These other components may be optionally added to the feed additive composition to assist the drying process and help the survival of DFM.

Further examples of other suitable components include one or more of: thickeners, gelling agents, emulsifiers, binders, crystal modifiers, sweeteners (including artificial sweeteners), rheology modifiers, stabilisers, anti-oxidants, dyes, enzymes, carriers, vehicles, excipients, diluents, lubricating agents, flavouring agents, colouring matter, suspending agents, disintegrants, granulation binders etc. These other components may be natural. These other components may be prepared by use of chemical and/or enzymatic techniques. In one embodiment the DFM and/or enzymes may be encapsulated. In one embodiment the feed additive composition and/or DFM and/or enzymes is/are formulated as a dry powder or granule as described in WO2007/044968 (referred to as TPT granules) - reference incorporated herein by reference.

In one preferred embodiment the DFM and/or enzymes for use in the present invention may be used in combination with one or more lipids.

For example, the DFM and/or enzymes for use in the present invention may be used in combination with one or more lipid micelles. The lipid micelle may be a simple lipid micelle or a complex lipid micelle.

The lipid micelle may be an aggregate of orientated molecules of amphipathic substances, such as a lipid and/or an oil.

As used herein the term "thickener or gelling agent" refers to a product that prevents separation by slowing or preventing the movement of particles, either droplets of immiscible liquids, air or insoluble solids. Thickening occurs when individual hydrated molecules cause an increase in viscosity, slowing the separation. Gelation occurs when the hydrated molecules link to form a three-dimensional network that traps the particles, thereby immobilising them.

The term "stabiliser" as used here is defined as an ingredient or combination of ingredients that keeps a product (e.g. a feed product) from changing over time.

The term "emulsifier" as used herein refers to an ingredient (e.g. a feed ingredient) that prevents the separation of emulsions. Emulsions are two immiscible substances, one present in droplet form, contained within the other. Emulsions can consist of oil-in-water, where the droplet or dispersed phase is oil and the continuous phase is water; or water-in-oil, where the water becomes the dispersed phase and the continuous phase is oil. Foams, which are gas-in- liquid, and suspensions, which are solid-in-liquid, can also be stabilised through the use of emulsifiers. As used herein the terra "binder" refers to an ingredient (e.g. a feed ingredient ) that binds the product together through a physical or chemical reaction. During "gelation" for instance, water is absorbed, providing a binding effect. However, binders can absorb other liquids, such as oils, holding them within the product. In the context of the present invention binders would typically be used in solid or low-moisture products for instance baking products: pastries, doughnuts, bread and others.

"Carriers" or "vehicles" mean materials suitable for administration of the DFM and/or enzymes and include any such material known in the art such as, for example, any liquid, gel, solvent, liquid diluent, solubilizer, or the like, which is non-toxic and which does not interact with any components of the composition in a deleterious manner.

The present invention provides a method for preparing a feed additive composition comprising admixing a DFM, a xylanase, a protease, a phytase and a amylase with at least one physiologically acceptable carrier selected from at least one of maltodextrin, limestone (calcium carbonate), cyclodextrin, wheat or a wheat component, sucrose, starch, Na₂S0₄, Talc, PVA, sorbitol, benzoate, sorbiate, glycerol, sucrose, propylene glycol, 1,3 -propane diol, glucose, parabens, sodium chloride, citrate, acetate, phosphate, calcium, metabisulfite, formate and mixtures thereof.

Examples of excipients include one or more of: microcrystalline cellulose and other celluloses, lactose, sodium citrate, calcium carbonate, dibasic calcium phosphate, glycine, starch, milk sugar and high molecular weight polyethylene glycols. Examples of disintegrants include one or more of: starch (preferably com, potato or tapioca starch), sodium starch glycollate, croscarmellose sodium and certain complex silicates.

Examples of granulation binders include one or more of: polyvinylpyrrolidone, hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC), sucrose, maltose, gelatin and acacia.

Examples of lubricating agents include one or more of: magnesium stearate, stearic acid, glyceryl behenate and talc. Examples of diluents include one or more of: water, ethanol, propylene glycol and glycerin, and combinations thereof.

The other components may be used simultaneously (e.g. when they are in admixture together or even when they are delivered by different routes) or sequentially (e.g. they may be delivered by different routes).

Preferably, when the feed additive composition of the present invention is admixed with another component(s), the DFM remains viable.

In one embodiment preferably the feed additive composition according to the present invention does not comprise chromium or organic chromium

In one embodiment preferably the feed additive according to the present invention does not contain glucanase.

In one embodiment preferably the feed additive according to the present invention does not contain sorbic acid.

Concentrates

The DFMs for use in the present invention may be in the form of concentrates. Typically these concentrates comprise a substantially high concentration of a DFM.

Feed additive compositions according to the present invention may have a content of viable cells (colony forming units, CFUs) which is in the range of at least 10⁴ CFU/g (suitably including at least 10⁵ CFU/g, such as at least 10⁶ CFU/g, e.g. at least l O⁷ CFU/g, at least 10⁸ CFU/g, e.g. at least 10⁹ CFU/g) to about 1θ'° CFU/g (or even about 10ⁿ CFU/g or about 10¹² CFU/g).

When the DFM is in the form of a concentrate the feed additive compositions according to the present invention may have a content of viable cells in the range of at least 10⁹ CFU/g to about 10¹² CFU/g, preferably at least 10¹⁰ CFU/g to about 10¹² CFU/g. Powders, granules and liquid compositions in the form of concentrates may be diluted with water or resuspended in water or other suitable diluents, for example, an appropriate growth medium such as milk or mineral or vegetable oils, to give compositions ready for use.

The DFM or feed additive composition of the present invention or the combinations of the present invention in the form of concentrates may be prepared according to methods known in the art. In one aspect of the present invention the enzymes or feed is contacted by a composition in a concentrated form.

The compositions of the present invention may be spray-dried or freeze-dried by methods known in the art.

Typical processes for making particles using a spray drying process involve a solid material which is dissolved in an appropriate solvent (e.g. a culture of a DFM in a fermentation medium). Alternatively, the material can be suspended or emulsified in a non-solvent to form a suspension or emulsion. Other ingredients (as discussed above) or components such as anti- microbial agents, stabilising agents, dyes and agents assisting with the drying process may optionally be added at this stage.

The solution then is atomised to form a fine mist of droplets. The droplets immediately enter a drying chamber where they contact a drying gas. The solvent is evaporated from the droplets into the drying gas to solidify the droplets, thereby forming particles. The particles are then separated from the drying gas and collected.

Subject

The term "subject", as used herein, means an animal that is to be or has been administered with a feed additive composition according to the present invention or a feedstuff comprising said feed additive composition according to the present invention. The term "subject", as used herein, means an animal. Preferably, the subject is a mammal, bird, fish or crustacean including for example livestock or a domesticated animal (e.g. a pet).

In one embodiment the "subject" is livestock.

The term "livestock", as used herein refers to any farmed animal. Preferably, livestock is one or more of cows or bulls (including calves), poultry, pigs (including piglets), poultry (including broilers, chickens and turkeys), birds, fish (including freshwater fish, such as salmon, cod, trout and carp, e.g. koi carp, and marine fish, such as sea bass), crustaceans (such as shrimps, mussels and scallops), horses (including race horses), sheep (including lambs).

In one embodiment the term livestock and/or poultry and/or chickens does not include egg layers.

In another embodiment the "subject" is a domesticated animal or pet or an animal maintained in a zoological environment.

The term "domesticated animal or pet or animal maintained in a zoological environment" as used herein refers to any relevant animal including canines (e.g. dogs), felines (e.g. cats), rodents (e.g. guinea pigs, rats, mice), birds, fish (including freshwater fish and marine fish), and horses.

In one embodiment the subject may be challenged by an enteric pathogen.

By way of example a subject may have one or more enteric pathogens present in its gut or digestive tract. For example a subject may have one or more enteric pathogens in its gut or digestive tract at a level which:

i) results in loss of performance of the animal and/or

ii) is at clinically relevant levels; or

iii) is at sub-clinical levels.

The enteric pathogen may be Clostridium perfringens for example. Performance

As used herein, "animal performance" may be determined by the feed efficiency and/or weight gain of the animal and/or by the feed conversion ratio and/or by the digestibility of a nutrient in a feed (e.g. amino acid digestibility) and/or digestible energy or metabolizable energy in a feed and/or by nitrogen retention and/or by animals ability to avoid the negative effects of necrotic enteritis and/or by the immune response of the subject.

Preferably "animal performance" is determined by feed efficiency and/or weight gain of the animal and/or by the feed conversion ratio.

By "improved animal perfonriance" it is meant that there is increased feed efficiency, and/or increased weight gain and/or reduced feed conversion ratio and/or improved digestibility of nutrients or energy in a feed and/or by improved nitrogen retention and/or by improved ability to avoid the negative effects of necrotic enteritis and/or by an improved immune response in the subject resulting from the use of feed additive composition of the present invention in feed in comparison to feed which does not comprise said feed additive composition.

Preferably, by "improved animal perfonriance" it is meant that there is increased feed efficiency and/or increased weight gain and/or reduced feed conversion ratio.

As used herein, the term "feed efficiency" refers to the amount of weight gain in an animal that occurs when the animal is fed ad-libitum or a specified amount of food during a period of time.

By "increased feed efficiency" it is meant that the use of a feed additive composition according the present invention in feed results in an increased weight gain per unit of feed intake compared with an animal fed without said feed additive composition being present. Feed Conversion Ratio (FCR)

As used herein, the term "feed conversion ratio" refers to the amount of feed fed to an animal to increase the weight of the animal by a specified amount. An improved feed conversion ratio means a lower feed conversion ratio.

By "lower feed conversion ratio" or "improved feed conversion ratio" it is meant that the use of a feed additive composition in feed results in a lower amount of feed being required to be fed to an animal to increase the weight of the animal by a specified amount compared to the amount of feed required to increase the weight of the animal by the same amount when the feed does not comprise said feed additive composition.

Nutrient digestibility

Nutrient digestibility as used herein means the fraction of a nutrient that disappears from the gastro-intestinal tract or a specified segment of the gastro-intestinal tract, e.g. the small intestine. Nutrient digestibility may be measured as the difference between what is administered to the subject and what comes out in the faeces of the subject, or between what is administered to the subject and what remains in the digesta on a specified segment of the gastro intestinal tract, e.g. the ileum.

Nutrient digestibility as used herein may be measured by the difference between the intake of a nutrient and the excreted nutrient by means of the total collection of excreta during a period of time; or with the use of an inert marker that is not absorbed by the animal, and allows the researcher calculating the amount of nutrient that disappeared in the entire gastro-intestinal tract or a segment of the gastro-intestinal tract. Such an inert marker may be titanium dioxide, chromic oxide or acid insoluble ash. Digestibility may be expressed as a percentage of the nutrient in the feed, or as mass units of digestible nutrient per mass units of nutrient in the feed.

Nutrient digestibility as used herein encompasses starch digestibility, fat digestibility, protein digestibility, and amino acid digestibility.

Energy digestibility as used herein means the gross energy of the feed consumed minus the gross energy of the faeces or the gross energy of the feed consumed minus the gross energy of the remaining digesta on a specified segment of the gastro-intestinal tract of the animal, e.g. the ileum. Metabolizable energy as used herein refers to apparent metabolizable energy and means the gross energy of the feed consumed minus the gross energy contained in the faeces, urine, and gaseous products of digestion. Energy digestibility and metabolizable energy may be measured as the difference between the intake of gross energy and the gross energy excreted in the faeces or the digesta present in specified segment of the gastro-intestinal tract using the same methods to measure the digestibility of nutrients, with appropriate correct ions for nitrogen excretion to calculate metabolizable energy of feed.

Nitrogen retention

Nitrogen retention as used herein means as subject's ability to retain nitrogen from the diet as body mass. A negative nitrogen balance occurs when the excretion of nitrogen exceeds the daily intake and is often seen when the muscle is being lost. A positive nitrogen balance is often associated with muscle growth, particularly in growing animals.

Nitrogen retention may be measured as the difference between the intake of nitrogen and the excreted nitrogen by means of the total collection of excreta and urine during a period of time. It is understood that excreted nitrogen includes undigested protein from the feed, endogenous proteinaceous secretions, microbial protein, and urinary nitrogen.

Survival

The term survival as used herein means the number of subject remaining alive. The term "improved survival" may be another way of saying "reduced mortality".

Carcass yield and meat yield

The term carcass yield as used herein means the amount of carcass as a proportion of the live body weight, after a commercial or experimental process of slaughter. The term carcass means the body of an animal that has been slaughtered for food, with the head, entrails, part of the limbs, and feathers or skin removed. The term meat yield as used herein means the amount of edible meat as a proportion of the live body weight, or the amount of a specified meat cut as a proportion of the live body weight. Weight gain

The present invention further provides a method of increasing weight gain in a subject, e.g. poultry or swine, comprising feeding said subject a feedstuff comprising a feed additive composition according to the present invention. An "increased weight gain^"' refers to an animal having increased body weight on being fed feed comprising a feed additive composition compared with an animal being fed a feed without said feed additive composition being present.

Necrotic enteritis

Necrotic enteritis is an acute or clironic enterotoxemia seen in chickens, turkeys and ducks worldwide, caused by Clostridium perfringens. Necrotic enteritis is often characterised by a fibrino-necrotic enteritis, usually of the mid- small intestine. Mortality may be 5-50%, usually around 10%. Infection occurs by faecal-oral transmission. Spores of the causative organism are highly resistant. Predisposing factors include coccidiosis/coccidiasis, diet (high protein), in ducks possibly heavy strains, high viscosity diets (often associated with high rye and wheat inclusions in the diet), contaminated feed and/or water, other debilitating diseases. The present invention relates to increasing the subject's resistance to necrotic enteritis. In other words, the present invention relates to avoiding or reducing the negative effect of necrotic enteritis.

The term "resistance to" as used herein may encompasses the term "tolerance of. Therefore in one embodiment the subject may not be resistant to necrotic enteritis but the subject may be able to tolerate the necrotic enteritis, i.e. without negative effects on performance of the subject.

In one embodiment the present invention relates to a feed additive composition according to the present invention for treating or preventing necrotic enteritis in a subject. Typically the subject will be one which has been or will be challenged with Clostridium perfringens and/or Eimeria species. Such challenge may come from the environment, or the application of live microorganisms in the feed or drinking water, e.g. when live coccidia vaccines are used. In another embodiment the present invention relates to a feed additive composition for preventing and/or treating coccidiosis and/or necrotic enteritis in a subject. The present invention yet further provides a method of preventing and/or treating necrotic enteritis and/or coccidiosis wherein an effective amount of a feed additive composition according to the present invention is administered to a subject. Immune response

Immune response as used herein means one of the multiple ways in which DFMs modulate the immune system of animals, including increased antibody production, up-regulation of cell mediated immunity, up-regulation of pro-inflammatory cytokines, and augmented toll-like receptor signalling. It is understood that immuno-stimulation of the gastro intestinal tract by DFMs may be advantageous to protect the host against disease, and that immuno-suppression of the gastro intestinal tract may be advantageous to the host because less nutrients and energy are used to support the immune function.

Preferably the immune response is a cellular immune response.

Preferably immune response is measure by looking at immune markers. Pathogenic bacteria

The term pathogenic bacteria as used herein means for example toxigenic Clostridia species, e.g. Clostridium perfringens and/or E. coli and/or Salmonella spp and/or Campylobacter spp. In one embodiment the pathogenic bacteria may be Avian pathogenic E. coli species.

The present invention may reduce populations of pathogenic bacteria in the gastrointestinal tract of a subject. Nutrient Exretion

In one embodment the present invention relates to reducing nutrient excretion in manure. This has positive effects on reducing environmental hazards. For example, in a preferred embodiment the present invention relates to reducing nitrogen and/or phosphorus content in the subject's manure. This, therefore, reduces the amount of nitrogen and/or phosphorus in the environment, which can be beneficial.

Probiotic For some applications, it is believed that the DFM in the composition of the present invention can exert a probiotic culture effect. It is also within the scope of the present invention to add to the composition of the present invention further probiotic and/or prebiotics. Here, a prebiotic is:

"a non-digestible food ingredient that beneficially affects the host by selectively stimulating the growth and/or the activity of one or a limited number of beneficial bacterid". The term "probiotic culture" as used herein defines live microorganisms (including bacteria or yeasts for example) which, when for example ingested or locally applied in sufficient numbers, beneficially affects the host organism, i.e. by conferring one or more demonstrable health benefits on the host organism. Probiotics may improve the microbial balance in one or more mucosal surfaces. For example, the mucosal surface may be the intestine, the urinary tract, the respiratory tract or the skin. The term "probiotic" as used herein also encompasses live microorganisms that can stimulate the beneficial branches of the immune system and at the same time decrease the inflammatory reactions in a mucosal surface, for example the gut.

Whilst there are no lower or upper limits for probiotic intake, it has been suggested that at least 10⁶-10¹², preferably at least 10⁶- 10¹⁰, preferably 10⁸-10⁹, cfu as a daily dose will be effective to achieve the beneficial health effects in a subject.

Isolated

In one aspect, suitably the enzyme or DFM used in the present invention may be in an isolated form. The term "isolated" means that the enzyme or DFM is at least substantially free from at least one other component with which the enzyme or DFM is naturally associated in nature and as found in nature. The enzyme or DFM of the present invention may be provided in a form that is substantially free of one or more contaminants with which the substance might otherwise be associated. Thus, for example it may be substantially free of one or more potentially contaminating polypeptides and/or nucleic acid molecules.

Purified In one aspect, preferably the enzyme and/or DFM according to the present invention is in a purified form. The term "purified^"' means that the enzyme and/or DFM is present at a high level. The enzyme and/or DFM is desirably the predominant component present in a composition. Preferably, it is present at a level of at least about 90%, or at least about 95% or at least about 98%, said level being determined on a dry weight/dry weight basis with respect to the total composition under consideration.

Tt is envisaged within the scope of the present invention that the embodiments of the invention can be combined such that combinations of any of the features described herein are included within the scope of the present invention. In particular, it is envisaged within the scope of the present invention that any of the therapeutic effects of the bacteria may be exhibited concomitantly.

NUCLEOTIDE SEQUENCE

The scope of the present invention encompasses nucleotide sequences encoding proteins having the specific properties as defined herein.

The term "nucleotide sequence" as used herein refers to an oligonucleotide sequence or polynucleotide sequence, and variant, homologues, fragments and derivatives thereof (such as portions thereof). The nucleotide sequence may be of genomic or synthetic or recombinant origin, which may be double-stranded or single-stranded whether representing the sense or anti- sense strand. The term "nucleotide sequence" in relation to the present invention includes genomic DNA, cDNA, synthetic DNA, and RNA. Preferably it means DNA, more preferably cDNA sequence coding for the present invention.

In a preferred embodiment, the nucleotide sequence when relating to and when encompassed by the per se scope of the present invention does not include the native nucleotide sequence according to the present invention when in its natural environment and when it is linked to its naturally associated sequence(s) that is/are also in its/their natural environment. For ease of reference, we shall call this preferred embodiment the "non-native nucleotide sequence". In this regard, the term "native nucleotide sequence" means an entire nucleotide sequence that is in its native environment and when operatively linked to an entire promoter with which it is naturally associated, which promoter is also in its native environment. However, the amino acid sequence encompassed by the scope of the present invention can be isolated and/or purified post expression of a nucleotide sequence in its native organism. Preferably, however, the amino acid sequence encompassed by scope of the present invention may be expressed by a nucleotide sequence in its native organism but wherein the nucleotide sequence is not under the control of the promoter with which it is naturally associated within that organism. Typically, the nucleotide sequence encompassed by the scope of the present invention is prepared using recombinant DNA techniques (i.e. recombinant DNA). However, in an alternative embodiment of the invention, the nucleotide sequence could be synthesised, in whole or in part, using chemical methods well known in the art (see Caruthers MH et al, (1980) Nuc Acids Res Symp Ser 215-23 and Horn T et al, (1980) Nuc Acids Res Symp Ser 225-232).

PREPARATION OF THE NUCLEOTIDE SEQUENCE

A nucleotide sequence encoding either a protein which has the specific properties as defined herein or a protein which is suitable for modification may be identified and/or isolated and/or purified from any cell or organism producing said protein. Various methods are well known within the art for the identification and/or isolation and/or purification of nucleotide sequences. By way of example, PGR amplification techniques to prepare more of a sequence may be used once a suitable sequence has been identified and/or isolated and/or purified.

By way of further example, a genomic DNA and/or cDNA library may be constructed using chromosomal DNA or messenger RNA from the organism producing the enzyme. If the amino acid sequence of the enzyme is known, labelled oligonucleotide probes may be synthesised and used to identify enzyme-encoding clones from the genomic library prepared from the organism. Alternatively, a labelled oligonucleotide probe containing sequences homologous to another known enzyme gene could be used to identify enzyme-encoding clones. In the latter case, hybridisation and washing conditions of lower stringency are used. Alternatively, enzyme-encoding clones could be identified by inserting fragments of genomic DNA into an expression vector, such as a plasmid. transforming enzyme-negative bacteria with the resulting genomic DNA library, and then plating the t a s formed bacteria onto agar plates containing a substrate for enzyme (i.e. maltose), thereby allowing clones expressing the enzyme to be identified. in a yet further alternative, the nucleotide sequence encoding the enzyme may be prepared synthetically by established standard methods, e.g. the phosphoroamidite method described by Beucage S.L. et al, (1981) Tetrahedron Letters 22, p 1859-1869, or the method described by Matthes et al, (1984) EMBO J. 3, p 801 -805. In the phosphoroamidite method, oligonucleotides are synthesised, e.g. in an automatic DNA synthesiser, purified, annealed, ligated and cloned in appropriate vectors.

The nucleotide sequence may be of mixed genomic and synthetic origin, mixed synthetic and cDNA origin, or mixed genomic and cDNA origin, prepared by ligating fragments of synthetic, genomic or cDNA origin (as appropriate) in accordance with standard techniques. Each ligated fragment corresponds to various parts of the entire nucleotide sequence. The DNA sequence may also be prepared by polymerase chain reaction (PGR) using specific primers, for instance as described in US 4,683,202 or in Saiki R et al, (Science (1988) 239, pp 487-491 ).

AMINO ACI D SEQUENCES

The scope of the present invention also encompasses amino acid sequences of enzymes having the specific properties as defined herein.

As used herein, the term "amino acid sequence" is synonymous with the term "polypeptide" and/or the term "protein". In some instances, the term "amino acid sequence" is synonymous with the term "peptide". In some instances, the term "amino acid sequence" is synonymous with the term "enzyme".

The amino acid sequence may be prepared/isolated from a suitable source, or it may be made synthetically or it may be prepared by use of recombinant DNA techniques. The protein encompassed in the present invention may he used in conjunction with other proteins, particularly enzymes. Thus the present invention also covers a combination of proteins wherein the combination comprises the protein/enzyme of the present invention and another protein/enzyme, which may be another protein/enzyme according to the present invention.

Preferably the amino acid sequence when relating to and when encompassed by the per se scope of the present invention is not a native enzyme. In this regard, the term "native enzyme" means an entire enzyme that is in its native environment and when it has been expressed by its native nucleotide sequence.

SEQUENCE IDENTITY OR SEQUENCE HOMOLOGY

The present invention also encompasses the use of sequences having a degree of sequence identity or sequence homology with amino acid sequence(s) of a polypeptide having the specific properties defined herein or of any nucleotide sequence encoding such a polypeptide (hereinafter referred to as a "homologous sequence(s)"). Here, the term "homologue" means an entity having a certain homology with the subject amino acid sequences and the subject nucleotide sequences. Here, the term "homology" can be equated with "identity".

The homologous amino acid sequence and/or nucleotide sequence should provide and/or encode a polypeptide which retains the functional activity and/or enhances the activity of the enzyme. In the present context, a homologous sequence is taken to include an amino acid sequence which may be at least 75, 85 or 90% identical, preferably at least 95 or 98% identical to the subject sequence. Typically, the homologues will comprise the same active sites etc. as the subject amino acid sequence. Although homology can also be considered in terms of similarity (i.e. amino acid residues having similar chemical properties/functions), in the context of the present invention it is preferred to express homology in terms of sequence identity. In the present context, a homologous sequence is taken to include a nucleotide sequence which may be at least 75, 85 or 90% identical, preferably at least 9 or 98% identical to a nucleotide sequence encoding a polypeptide of the present invention (the subject sequence). Typically, the homologues will comprise the same sequences that code for the active sites etc. as the subject sequence. Although homology can also be considered in terms of similarity (i.e. amino acid residues having similar chemical properties/functions), in the context of the present invention it is preferred to express homology in terms of sequence identity.

Homology comparisons can be conducted by eye, or more usually, with the aid of readily available sequence comparison programs. These commercially available computer programs can calculate % homology between two or more sequences.

% homology may be calculated over contiguous sequences, i.e. one sequence is aligned with the other sequence and each amino acid in one sequence is directly compared with the corresponding amino acid in the other sequence, one residue at a time. This is called an "ungapped" alignment. Typically, such ungapped alignments are performed only over a relatively short number of residues.

Although this is a very simple and consistent method, it fails to take into consideration that, for example, in an otherwise identical pair of sequences, one insertion or deletion will cause the following amino acid residues to be put out of alignment, thus potentially resulting in a large reduction in % homology when a global alignment is performed. Consequently, most sequence comparison methods are designed to produce optimal alignments that take into consideration possible insertions and deletions without penalising unduly the overall homology score. This is achieved by inserting "gaps" in the sequence alignment to try to maximise local homology.

However, these more complex methods assign "gap penalties" to each gap that occurs in the alignment so that, for the same number of identical amino acids, a sequence alignment with as few gaps as possible - reflecting higher relatedness between the two compared sequences - will achieve a higher score than one with many gaps. "Affine gap costs" are typically used that charge a relatively high cost for the existence of a gap and a smaller penalty for each subsequent residue in the gap. This is the most commonly used gap scoring system. High gap penalties will of course produce optimised alignments with fewer gaps. Most alignment programs allow the gap penalties to be modified. However, it is preferred to use the default values when using such software for sequence comparisons. Calculation of maximum % homology therefore firstly requires the production of an optimal alignment, taking into consideration gap penalties. A suitable computer program for carrying out such an alignment is the Vector NTI (Invitrogen Corp.). Examples of software that can perform sequence comparisons include, but are not limited to, the BLAST package (see Ausubel et al 1999 Short Protocols in Molecular Biology, 4th Ed - Chapter 18), BLAST 2 (see FEMS Microbiol Lett 1999 174(2): 247-50; FEMS Microbiol Lett 1999 177(1): 187-8 and tatiana@ncbi.nlm.nih.gov). FASTA (Altschul et al 1990 J. Mol. Biol. 403-410) and AlignX for example. At least BLAST, BLAST 2 and FASTA are available for offline and online searching (see Ausubel et al 1999, pages 7-58 to 7-60). Although the final % homology can be measured in terms of identity, the alignment process itself is typically not based on an all-or-nothing pair comparison. Instead, a scaled similarity score matrix is generally used that assigns scores to each pairwise comparison based on chemical similarity or evolutionary distance. An example of such a matrix commonly used is the BLOSUM62 matrix - the default matrix for the BLAST suite of programs. Vector NTI programs generally use either the public default values or a custom symbol comparison table if supplied (see user manual for further details). For some applications, it is preferred to use the default values for the V ector NTI package.

Alternatively, percentage homologies may be calculated using the multiple alignment feature in Vector NTI (Invitrogen Corp.), based on an algorithm, analogous to CLUSTAL (Higgins DG & Sharp PM (1988), Gene 73(1), 237-244).

Once the software has produced an optimal alignment, it is possible to calculate % homology, preferably % sequence identity. The software typically does this as part of the sequence comparison and generates a numerical result.

Should Gap Penalties be used when determining sequence identity, then preferably the following parameters are used for pairwise alignment: FOR BLAST

GAP OPEN 0

GAP EXTENSION 0

In one embodiment, CLIJSTAL may be used with the gap penalty and gap extension set as defined above.

Suitably, the degree of identity with regard to a nucleotide sequence is determined over at least 20 contiguous nucleotides, preferably over at least 30 contiguous nucleotides, preferably over at least 40 contiguous nucleotides, preferably over at least 50 contiguous nucleotides, preferably over at least 60 contiguous nucleotides, preferably over at least 100 contiguous nucleotides.

Suitably, the degree of identity with regard to a nucleotide sequence may be determined over the whole sequence.

HYBRIDISATION

The present invention also encompasses sequences that are complementary to the nucleic acid sequences of the present invention or sequences that are capable of hybridising either to the sequences of the present invention or to sequences that are complementary thereto. The term "hybridisation" as used herein shall include "the process by which a strand of nucleic acid joins with a complementary strand through base pairing" as well as the process of amplification as earned out in polymerase chain reaction (PGR) technologies. The present invention also encompasses the use of nucleotide sequences that are capable of hybridising to the sequences that are complementary to the sequences presented herein, or any derivative, fragment or derivative thereof.

The term "variant" also encompasses sequences that are complementary to sequences that are capable of hybridising to the nucleotide sequences presented herein.

Preferably, complementary sequences are those capable of hybridising under stringent conditions (e.g. 50°C and 0.2xSSC { lxSSC - 0.15 M NaCl, 0.015 M Na₃citrate pH 7.0}) to the nucleotide sequences presented herein.

More preferably, complementary sequences are those that are capable of hybridising under high stringency conditions (e.g. 65°C and O. lxSSC { lxSSC = 0.15 M NaCl, 0.015 M Na₃citrate pH 7.0}) to the nucleotide sequences presented herein. In a more preferred aspect, the present invention covers nucleotide sequences that can hybridise to the nucleotide sequence of the present invention, or the complement thereof, under high stringent conditions (e.g. 65°C and O. lxSSC).

EXAMPLES

Example 1

Materials and Methods Three thousand six hundred one-day-old Cobb male chicks were purchased from a commercial hatchery. At study initiation, fifty males were allocated to each treatment pen by blocks. The study consisted of the following treatments (Table 1 ): Table 1. Experimental design of Example 1.

Phytase from E. coli.

² Amylase from Bacillus licheniformis, xylanase from Trichoderma reesei, protease from Bacillus subtilis.

³ Enviva Pro ® is combination of Bacillus subtilis strains Bs2084, LSSAOl and 15AP4, provided by Danisco A/S.

⁴ Axtra XAP ® provided by Danisco A/S. Bird weights by pen were recorded at study initiation, 23 d, 35 d, and termination (42d). The pen was the unit of measure. Broiler diets were fed as crumbles (starter) or pellets (grower and finisher). Diets met or exceeded NRC standards (Table 2). The mixer was flushed to prevent cross contamination of diets. All treatment feeds were mixed using a Davis S-20 mixer and pelleted using a California Pellet Mill (cold pellet temperature 65-70 C). Samples were collected from each treatment diet, from the beginning, middle, and end of each batch and blended together to confirm enzyme activities and En viva Pro presence in feed.

Table 2. Experimental diet composition of Example 1.

Ingredient (%) Starter Grower Finisher

Maize 53.62 57.87 59.82

Maize DDGS 10.00 10.00 10.00

Soybean Meal 49%CP 26.93 23.97 21.36

Ampro 55 5.00 5.00 5.00

Soy oil 2.07 0.91 1.74

Lysine 0.24 0.24 0.24

DL-methionine 0.21 0.19 0.18

L-threonine 0.01 0.01 0.01

Salt 0.30 0.34 0.35

Limestone 1.04 1.07 0.94

Dicalcium phosphate 0.26 0.1 1 0.02

Vitamin and trace mineral premix 0.33 0.33 0.33

Calculated Nutrient Composition (%)

CP 22.60 21.50 20.39

Energy, kcal/kg 3060 3025 3 100

Digestible lysine 1.36 1.26 1 .21

Digestible methionine 0.58 0.61 0.53

Digestible threonine 0.83 0.83 0.80

Birds received feed ad-libitum appropriate to the treatment from day 0 to 42. Enzymes and Enviva Pro were provided by Danisco in the appropriate mixtures and levels for all experimental treatments. All diets contained 500 FTU of E. coli phytase in the background. The pens were arranged within the facility to prevent direct contact in order to avoid contamination. A change from starter to grower occurred on day 23. Grower diet was replaced with the finisher diet on day 35. At each feed change, feeders were removed from pens by block, weighed back, emptied, and refilled with the appropriate treatment diet. On the final day of the study feed was weighed. Pens were checked daily for mortality. When a bird was culled or found dead, the date and removal weight (kg) were recorded. A gross necropsy was performed on all dead or culled birds to determine the sex and probable cause of death. Signs of Necrotic Enteritis were noted.

All pens had approximately 4 inches of built up litter with a coaling of fresh pine shavings. All birds were spray vaccinated prior to placement into pens with a commercial coccidiosis vaccine (Coccivac-B). On days 20, 21 , and 22 all birds, except Treatment 1, were dosed with a broth culture of C. perfringens, A field isolate of C. perfringens known to cause NE and originating from a commercial broiler operation was utilized as the challenge organism. Fresh inoculum was used each day. The titration levels were approximately 1.0 X 10^8"9. Each pen received the same amount of inoculum. The inoculum was administered by mixing into the feed found in the base of the tube feeder. On day 23, five birds from each pen were selected, euthanized, group weighed, and examined for the degree of presence of Necrotic Enteritis lesions. The scoring was based on a 0 to 3 score, with 0 being normal and 3 being the most severe (0 = none, 1 = mild, 2 = moderate, 3 = marked/severe; Hofacre et al., 2003 J. Appl. Poult. Res. 12:60-64). No concomitant drug therapy was used during the study.

Means were separated using pair wise t-tests. Significant differences were considered at P<0.05. Pens were used as the experimental unit.

Results

Figure 1 shows the necrotic enteritis lesion scores of broiler chickens in a necrotic enteritis challenge model, based on a 0 to 3 score system. Pooled SEM=0.15

The challenged control treatment increased lesion scores compared to the unchallenged control treatment. Addition of DFMs with a combination of a xylanase, amylase, protease and phytase reduced lesion scores compared to all other treatments. Addition of DFMs in combination with the enzymes reduced lesion scores compared DFMs alone or enzymes by themselves. Figure 2 shows the body weight gain of broiler chickens in a necrotic enteritis challenge model. Pooled SEM=28.6

Figure 2 shows that a combination of the DFM (Enviva Pro®) with a combination of a xylanase, an amylase, a protease and a phytase significantly improved body weight gain (BW gain) in broiler chickens challenged with Clostridium perfi'ingens compared with the challenged control - even resulting in BW gain which was improved over a negative control (i.e. an unchallenged control). This was significantly better than any other treatments. Figure 3 shows the feed conversion ratio of broiler chickens in a necrotic enteritis challenge model. Pooled SEM=0.016

The combination of Enviva Pro (DFM) with a xylanase, amylase, protease and phytase significantly improved (reduced) FCR (g BW gain / g feed intake) of broilers from hatch to 42 d compared to the challenged control, and enzymes by themselves and the other treatments.

Example 2.

Materials and Methods

Cobb 500 male broiler chicks were obtained from a commercial hatchery. A total of 26 chicks were randomly assigned to one of 8 replicate pens per treatment. Floor pens (16 ft²/pen) were located in a curtain-sided house containing controlled heating, circulating fans, heat lamps and fresh wood shavings. Birds were exposed to fluorescent lighting in a 24 h light cycle for the first four days and then 16 light:8 hour dark cycle for the remainder of the experiment. Feed was provided in bell feeders and water supplied via nipple drinkers ad libitum. A 5X dose of Coccivac-B (Intervet) was administered manually with a syringe into the oral cavity of chicks at one day of age. Table 3. Experimental design of Example 2.

1 5X 500 FTU lcg None None

2 5X 500 FTU/kg None Enviva Pro

(7.5 x 10⁴

CFU/g)

3 5X 500 FTU/kg Xylanase⁴ (1000 u/kg) None

Amylase⁴ (1800 u/kg)

Protease⁴ (5000 u/kg)

4 5X 500 FTU/kg Xylanase⁴ ( 1000 u/kg) Enviva Pro

Amylase⁴ (1800 u/kg) (7.5 x 10⁴ Protease⁴ (5000 u/kg) CFU/g)

Phytase from E. coli.

² Amylase from Bacillus amyloliquefaciens, xylanase from Trichoderma reesei, protease from Bacillus subiilis.

⁴ Avizyme 1505 ® provided by Danisco A/S.

Chicks were fed diets with or without either Enviva Pro or xylanase, amylase, and protease (Avizyme 1502; Table 3). Enzymes and Enviva Pro were provided by Danisco in the appropriate mixtures and levels for all experimental treatments. All diets contained 500 FTU of E. coli phytase. The pens were arranged within the facility to prevent direct contact in order to avoid contamination.

All diets were com-soybean meal-DDGS based diets. Starter diets were provided during the study (dl-20). Diets were pelleted (65 - 70°C) and crumbled. Samples were collected from each treatment diet from the beginning, middle, and end of each batch and blended together to confirm enzyme activities and Enviva Pro presence in feed.

Table 4. Experimental diet composition of Example 2.

Starter Grower Finisher

Ingredient (%) (0-20 d) (20-38 d) (38-48 d) Maize 50.60 52.3 57.40

Wheat Middilings 1.33 1.03 1.32

Maize DDGS 7.00 7.00 7.00

Soybean Meal 34.60 33.50 28.60

Vegetable fat 2.50 2.50 2.50

Limestone 1.41 1.38 1.09

MD-Phosphate 1.20 1.00 0.84

DL- methionine 0.31 0.27 0.27

Salt 0.46 0.46 0.46

L-Lysine 0.29 0.23 0.28

Vitamin and Trace Mineral Premix 1.50 1.50 1.50

Calculated Nutrient Composition (%)

ME poultry, kcal/kg 2950 3000 3040

CP 23.0 22.5 20.4

Calcium 0.85 0.81 0.75

Av. Phosphorus 0.38 0.35 0.32

TSAA 0.98 0.94 0.89

Lysine 1.36 1.29 1.20

Methionine 0.62 0.59 0.56

Body weights and feeder weights were recorded on day 1, 1 1 , 20, 38 and 48 for calculation of feed intake, body weight gain and feed conversion. Mortality and culls were monitored on a daily basis and used to adjust for feed consumption and gain. One bird from six replicate pens was euthanized by cervical dislocation for collection of mucosal scrapings on days 1 1 and 20. Mucosal scrapings were collected from the ileum (Meckel's diverticulum to the ileo-cecal junction). The ileum was excised and cut along its length to expose the lumen and then flushed quickly and gently with PBS to remove digesta. The edge of a microscope slide was used to remove the mucosal layer by scraping along the length of the excised tissue section. The mucosal layer was immediately freeze clamped between aluminium plates in liquid N to preserve RNA integrity and stored in individual whirl-pack bags. Frozen tissue samples were stored in liquid N during sampling and at -80 C prior to analysis. Total RNA from mucosal scraping was isolated using the Trizol reagent (Invitrogen) using a mechanical homogenize!" for tissue disruption. Total RNA (0.5 μg) was reverse transcribed to complementary D A using i Script (Bio-Rad) according to the manufacturer's recommendations. The mRNA abundance of secreted inflammatory cytokine genes (interleukin- 10, interferon-γ and interleukin- 17) was assessed using chicken-specific primers. Additionally, TATA-BP, HPRT-1 and β-actin mRNA abundance was measured for data normalization using geNorm software. The fold-change in mRNA abundance in gene expression was determined using the modified delta-delta Ct equation as described by Rudrappa and Humphrey (2007) J. Nutr. 137: 427-432 and log transformed for data analysis.

Means were separated using pair wise t-tests. Significant differences were considered at P<0.05. Birds were used as the experimental unit for mRNA data.

Results

Figure 4 shows mRNA abundance of interferon-gamma gene in ileal mucosal scrapings of broiler chickens.

Age l id: Pooled SEM=0.1

Age 20 d: Pooled SEM=0.6

The combination of Enviva Pro and xylanase, amylase, protease + phytase upregulated IFR-g expression in the ileum of 1 1 -d-old-broilers that received 5 times a live coccidiosis vaccine at hatch compared to the negative control, Enviva Pro + phytase, and xylanase, amylase, protease + phytase. At 21 d, Enviva Pro + phytase, and the combination of Enviva Pro and xylanase, amylase, protease + phytase down regulated IFR-g expression in the ileum compared to the negative control. These data suggest that modulation of immune response may be one of the mechanisms of improved performance of DFMs in combination with the 4 enzymes in broilers.

Figure 15 shows feed conversion ratio of broiler chickens at 48 d of age. Age 48 d: Pooled SEM-0.041 Example 3

Materials and Methods One digestibility trial with broiler chickens was conducted to determine the effects of dietary enzymes and DFMs treatments on nutrient utilisation. The cages were housed in environmentally controlled rooms. The birds received 20-hour fluorescent illumination and, allowed free access to the diets and water. On day 1 , a broiler live coccidiosis vaccine was given to all chicks via drinking water. Paper was provided on cage wire-floor for the first three days to enable recycling of Eimeria Oocystes. The study consisted of the following treatments (Table 5).

Table 5. Experimental design of Example 3.

8 500 FTU/kg Xylanase" (2000 u/kg) Enviva Pro

Amylase 2⁵ (200 u/kg) (7.5 x 10⁴ CFU/g)

Protease⁵ (5000 u/kg)

Phytase from E. coli.

² Amylase 1 from Bacillus amyloliquefaciens, amylase 2 from Bacillus licheniformis, xylanase from Trichoderma reesei, protease from Bacillus subtilis.

³ Enviva Pro ® is combination of Bacillus subtilis strains Bs2084, LSSAO l and 15AP4, provided by Danisco A/S.

⁴ Avizyme 1 05 ® provided by Danisco A/S.

⁵ Axtra XAP ® provided by Danisco A/S.

A total of 192 birds were individually weighed and assigned on the basis of body weight to 48 cages (4 birds/ cage). The 8 dietary treatments were then randomly assigned to six cages each. Birds received starter feed ad-libitum appropriate to the treatment from 0 to 21 days. Enzymes and Enviva Pro were provided by Danisco in the appropriate mixtures and levels for all experimental treatments. All diets contained 500 FTU of E. coli phytase. The pens were arranged within the facility to prevent direct contact in order to avoid contamination. Birds were fed starter diets (Table 6) in mash form throughout the experiment.

Table 6. Experimental diet composition of Example 3.

Ingredient (%) Starter

Maize 46.22

Wheat middlings 6.73

Maize DDGS 7.00

Soybean Meal 48%CP 32.81

Maize starch/enzyme/DFM premix 0.30

Animal/vegetable fat blend (50:50) 3.00

L-Lysine.HCl 0.27

DL-methionine 0.30

L-threonine 0.11

Titanium dioxide 0.30

Salt 0.34 Limestone 1.12

Dicalcium phosphate 1.20

Vitamin and trace mineral premix 0.30

Calculated Nutrient Composition (%)

CP 23.00

ME, kcal/kg 2950

Calcium 0.85

Available phosphorus 0.38

Sodium 0.18

Digestible lysine 1.21

Digestible methionine 0.62

Digestible TSAA 0.86

Digestible threonine 0.76

On day 21 , four birds per cage were euthanized by intracardial injection of sodium pentobarbitone and contents of the lower ileum were expressed by gentle flushing with distilled water. Digesta from birds within a cage were pooled, resulting in six samples per dietary treatment. The digesta samples were frozen immediately after collection, lyophilised and processed. Digesta samples and diets were analysed for Ti, DM, GE, starch, fat, N and amino acids, excluding tryptophan, as per standard procedures. Calculation of ileal digestibility coefficients was performed as reported by Ravindran et al. (2005), based on the concentration of indigestible Ti. The energy contribution of starch, fat and protein to ileal digestible energy was calculated based on mean gross energy of starch (4.2 kcal/g), fat (9.4 kcal/g), or protein (5.5 kcal/kg). The improvement of digestible amino acids in response to enzymes and DFMs was expressed in relation to the amount of non-digested amino acids at the ileal level; the slope of that linear function was used as an indicator of the effects of the additives on amino acid digestibility.

Means were separated using pair wise t-tests. Significant differences were considered at P<0.05. Cages were used as the experimental unit.

Results Figure 5 shows apparent ileal digestible energy of broiler chickens at 21 d of age.

Pooled SEM=0.027 The addition of Enviva Pro (a DFM) in combination with an amylase, xylanase, protease and phytase exhibited commercially relevant increments of ileal digestible energy compared with the enzymes by themselves and the negative controls. These data indicates that DFMs improved the effects of these exogenous enzymes on the energy digestibility of poultry diets. For the avoidance of doubt Amylase 2 is through use of the amylase in AxtraXAP and Amylase 1 is through use of the amylase in Avizyme 1502.

Figure 6 show increments of ileal amino acid digestibility for three dietary treatments versus the control treatment as function of ileal undigested amino acids in the control treatment using 21 -d-old broiler chickens.

The figure presents the improvement on ileal amino acid digestibility of dietary treatments with respect to the undigested fraction of amino acids in the ileum of broilers in the control treatment. Each point within a treatment represents one of the measured amino acids. The addition of Enviva Pro on top of xylanase, amylase 2. protease + phytase increased the ileal digestibility of amino acids (+1 1.3%) compared to Enviva Pro + Phytase (+3.6%) and xylanase, amylase 2, protease + phytase by themselves (i.e. without DFM) (+4.7%). These data indicates that DFMs improved the efficacy of these exogenous enzymes to increase amino acid digestibili ty of poultry diets. Figure 7 shows the improvement of ileal digestible energy with respect to the control treatment using 21-d-old broiler chickens.

The figure presents the increment of ileal digestible energy of each dietary treatment compared a negative control treatment with phytase. Additionally, the calculated contributions of energy from starch, fat or protein are presented. Addition of Enviva Pro in combination with xylanase, amylase 2, protease + phytase increased the ileal digestible energy compared to the Enviva Pro + phytase treatment and the xylanase, amylase 2, protease + phytase by themselves treatment. Addition of Enviva Pro in combination with xylanase, amylase 1, protease + phytase produced commercially important increments on ileal digestible energy versus the enzymes by themselves. These data indicate an improved ability of the 4 enzymes to increase the ileal digestible energy of broiler diets in the presence of DFMs.

Example 4

Materials and Methods One digestibility trial with broiler chickens was conducted to determine the effects of dietary enzymes and DFMs treatments on nutrient utilisation. The cages were housed in environmentally controlled rooms. The birds received 20-hour fluorescent illumination and, allowed free access to the diets and water. On day 1 , a broiler live coccidiosis vaccine was given to all chicks via drinking water. Paper was provided on cage wire-floor for the first three days to enable recycling of Eimeria Oocystes. The study consisted of the following treatments (Table 7)

Table 7. Experimental design of Example

OJ

Phytase from E. coli.

² Amylase 1 from Bacillus amyloliquefaciens. amylase 2 from Bacillus licheniformis, xylanase from Trichoderma reesei, protease from Bacillus subtilis.

⁴ Avizyme 1505 ® provided by Danisco A/S.

" Axtra XAP ® provided by Danisco A/S.

A total of 144 birds were individually weighed and assigned on the basis of body weight to 36 cages (4 birds/ cage). The 6 dietary treatments were then randomly assigned to six cages each. Birds received starter feed ad-libitum appropriate to the treatment from 0 to 21 days. Enzymes and Enviva Pro were provided by Danisco in the appropriate mixtures and levels for all experimental treatments. The pens were arranged within the facility to prevent direct contact in order to avoid contamination. Birds were fed starter diets (Table 6) in mash form throughout the experiment.

Table 8. Experimental diet composition of Example 4.

Ingredient (%) Starter

Maize 46.22

Wheat middlings 6.73

Maize DDGS 7.00

Soybean Meal 48%CP 32.81

Maize starch/enzyme/DFM premix 0.30

Animal/vegetable fat blend (50:50) 3.00

L-Lysine.HCl 0.27

DL-methionine 0.30

L-threonine 0.1 1

Titanium dioxide 0.30 Salt 0.34

Limestone 1.12

Dicalcium phosphate 1.20

Vitamin and trace mineral premix 0.30

Calculated Nutrient Composition (%)

CP 23.00

ME, kcal/kg 2950

Calcium 0.85

Available phosphorus 0.38

Sodium 0.18

Digestible lysine 1.21

Digestible methionine 0.62

Digestible TSAA 0.86

Digestible threonine 0.76

Feed intake and total excreta output were measured quantitatively per cage over four consecutive days (from day 17 to 20) for the determination of nitrogen-corrected apparent metabolizabie energy (AMEn) and Nitrogen retention. Daily excreta collections were pooled within a cage, mixed in a blender and sub-sampled. Each sub sample was lyophilized, ground to pass through a 0.5 mm sieve and stored in airtight plastic containers at - 4 C pending analysis. Processed samples were analysed for DM, GE and N, using standard procedures.

Means were separated using pair wise t-tests. Significant differences were considered at PO.05. Cages were used as the experimental unit.

Results

Figure 8 shows nitrogen-corrected apparent metabolizabie energy AMEn of dietary treatments fed to 17 to 21-d-old broiler chickens. Pooled SEM=0.015

Addition of Enviva Pro in combinations with xylanase, amylase, protease + phytase increased the AMEn of diets in response to enzymes compared to the negative control diet. In particular, addition of Enviva Pro in combination with xylanase, amylase 2, protease + phytase increased the AM En of diets in response to enzymes compared to diets with only Enviva Pro.

Figure 9 shows nitrogen retention of 17 to 21 -d-old broiler chickens. Pooled SEM=0.006

Addition of Enviva Pro in combination with xylanase, amylase, protease + phytase increased the nitrogen retention of broiler chickens in response to enzymes compared to the negative control diet. In particular, addition of Enviva Pro on top of xylanase, amylase 2, protease + phytase increased the nitrogen retention of broilers in response to enzymes compared to broilers fed diets with Enviva Pro only.

Example 5

Materials and Methods

Ross 308 male broiler chicks were obtained from a commercial hatchery. A total of 10 chicks were randomly assigned to one of 6 replicate cages per treatment. Birds were exposed to fluorescent lighting in a 24 h light cycle for the first four days and then 16 light:8 hour dark cycle for the remainder of the experiment. Feed and water were supplied ad libitum. The experimental design consisted of the following treatments.

Table 9. Experimental design of Example 5.

Treatment Coccidiosis Coccidio Phytase¹ Additional enzyme DFM' vaccine stat

1 None None 500 FTU/kg None None

2 5X None 500 FTU/kg None None

~! 5X Salinomyci 500 FTU/kg None None

n

4 5X None 500 FTU/kg None Enviva Pro

(7.5 x 10⁴

CFU/g) 5 5X None 500 FTU/kg Xylanase⁴ (1000 u/kg) None

Amylase⁴ (1800 u/kg)

Protease⁴ (5000 u/kg)

6 5X None 500 FTU/kg Xylanase⁴ (1000 u/kg) Enviva Pro

Amylase⁴ (1800 u/kg) (7.5 x 10⁴ Protease⁴ (5000 u/kg) CFU/g)

Phytase from E. coli.

² Amylase from Bacillus amyloliquefaciens, xylanase from Trichoderma reesei, protease from Bacillus subtilis.

⁴ Avizyme 1505 ® provided by Danisco A/S.

In treatments 2 to 6, an overdosed (recommended dose x5) coccidiosis vaccine (B, Intervet) was administered manually with a syringe into the oral cavity of chicks at one day of age. In treatment 2, Salinomycin (Bio-cox) was used at the approved level (60 g/MT) as a coccidiostat. The pens were arranged within the facility to prevent direct contact in order to avoid cross contamination with Eimeria oocysts and DFMs. Enzymes and Enviva Pro were provided by Danisco A/S in the appropriate mixtures and levels for all experimental treatments. All diets contained 500 FTU of E. coli phytase in the background.

Table 10. Experimental diet composition of Example 5.

Ingredient (%) Starter

Maize 53.18

Maize DDGS 10.00

Soyabean Meal 48%CP 32.05

Soyabean Oil 1.07

L-Lysine HC1 0.31

DL-methionine 0.31

L-threonine 0.12

Salt 0.33 Limestone 1.14

Dicalcium Phosphate 1.19

Vitamin and Trace Mineral Premix 0.30

Calculated Nutrient Composition (%)

CP 23.00

ME, kcal/kg 2950

Calcium 0.85

Available phosphorus 0.38

Sodium 0.18

Digestible lysine 1.21

Digestible methionine 0.63

Digestible TSAA 0.86

Digestible threonine 0.76

A total of 2 birds per replicate cage were euthanized at 14 d of age for collection of mucosal scrapings from mid-ileum. lleums were flushed with distilled water and cut open with a pair of scissors. Opened sections were laid flat on a clean glass plate. Mucosa was carefully scraped from the mid region of ileum with the long edge of a glass slide. Each sample was stored in 2 ml of RNA later (Ambion) and frozen in a -80 C freezer. Samples were thawed on ice. Total RNA was isolated with Trizol reagent according to standard protocols. Integrity of RNA was determined on an agarose gel. RNA was reverse transcribed with the MMLV reverse transcriptase. Expression of mucin (MUC2) was determined by real time PGR on a Biorad real-time MylQ machine.

Means were separated using pair wise t-tests. Significant differences were considered at PO.05. Birds were used as the experimental unit for mRNA data. Results

Figure 10 shows mRNA abundance of MUC2 gene in ileal mucosal scrapings of broiler chickens at 14 d of age. Pooled SEM=0.14 Addition of Enviva Pro in combination with xylanase, amylase, protease + phytasc down regulated the expression of MUC 2 in the ileum of broilers challenged with a 5 X dose of a live coccidiosis vaccine compared to the challenged control. These data suggest that a reduction of endogenous amino acid losses due to reduced mucin secretion may be responsible for improved performance of broilers receiving combinations of DFMs and the 4 enzymes.

Example 6 Materials and Methods

Tissue samples were taken from broiler chicks from the trial presented in Example 1 at 23 days of age. Treatment specifications are presented in Table 1. The jejunum, pancreas and liver were removed from 2 birds from every pen and the mucosa pooled resulting in eight samples per treatment. The samples were rinsed in buffer solution (PBS) immersed in a tissue storage reagent (RNAlater) according to manufacturer's protocol and stored at -80°C. Total RNA was isolated from each tissue sample using a single step phenol-chloroform extraction method as described by Chomczynski and Saachi (1987; Anal. Biochem. 162:156-9). Concentration of the RNA was determined by measuring the absorbance at 260nm (Nanodrop) and monitored for integrity by gel electrophoresis on 1.2% agarose gels. Only RNA of sufficient purity and having a ratio of absoiption at 260nm vs. 280nm greater than 1.87 were considered for use.

Microarrays were manufactured using 70 base pair oligo-nucleotides (Opereon Biotechnologies Inc) according to the protocol described by Druyan et al. (2008; Poult. Sci. 87:2418-29). The experimental design of the array was a complete interwoven loop design as described by Garosi et al. (2005; Br. J. Nutr. 93:425-32) which each sample is compared directly with the others in a multiple pair wise fashion allowing all treatments to be compared. The samples were labelled according to the method described by Druyan et al. (2008; Poult. Sci. 87:2418-29) in that that half the samples would be labelled with Cy3 and half with Cy5 which are fluorescent dyes of cyanine. Hybridisation was carried out using the Pronto Plus! Microarray Hybridisation Kit prior to the addition of Cy3 and Cy5 labelled cDNA probes and covered with a clean glass coverslip (Lifterslip) and left to hybridise for 16 hours. The microarrays were then scanned on a Scan Array Gx PLUS icroarray Scanner set to 65% laser power to acquire images.

Total RNA from individual samples was reversed transcribed to produce cDNA which was then used as a template for the qPCR amplifications as described by Druyan et al. (2008; Poult. Sci. 87:241 8-29). Thermocycling parameters were optimised for each gene and each gene was amplified independently in duplicate within a single instrument run.

Data files were generated from the scanned images of the microarrays but extracting the intensity raw data for each slide and dye combination using ScanAlyze Softare. Intensity data files were then analysed using JMP Genomics including and initial log2 transfonriation. Data nonnalisation was performed using locally- weighted regression and smoothing first within array and across all arrays. The resulting normalised log2 intensities were analysed using a mixed model ANOVA.

Mean intensities were compared using a threshold of significance based on Bongerroni correction of P=0.05. For the complete array, including all replicates, a mean by grid intensity was calculated for each gene using the 3 side by side probes, resulting in a total of four replicated means, one from each grid, per gene. Data for the Ct ratio from the samples in duplicate (sample gene Ct: Sample GAPDH Ct) depending on treatment were subjected to one way ANOVA.

Results Expression data was collected using the microarray platform and a "heat map" produced to visualise the data for the jejunum (Figure 16) and pancreas (Figure 17). Relative expression levels of six genes of interest were converted to visual cues based on the scale seen in Figure 16. Lowly expressed genes are are marked with a minus sign ("-"), and highly expressed genes are marked with a plus sign ("+"); whereas a greater gray intensity depicts a greater difference from the mean expression level of the treatments. The genes that were measured and their purported functions are seen in Table 1 1. Real-time PGR was used to validate the gene expression shown in the heat map for sucrase-isomaltase (SI) and amylase 2A (AMY2a) and were highly correlated to the anay data. Table 1 1. Purported function of genes measured.

Figure 17 shows a heat map of expression profile of chicken alpha amylase for all treatments in pancreas at 23 days of age. In Figures 16 and 1 7 the key is as follows:

Unchallenged control= Unchallenged Control + phytase

CC = Challenged Control + phytase

CC+ Amylase = Challenged Control + phytase + amylase

CC+ XAP = Challenged Control + phytase + xylanase + amylase + protease

CC+ EP = Challenged Control + phytase + Enviva Pro

CC+ EP +Amylase = Challenged Control + phytase + amylase + Enviva Pro

Pro The expression of oligo-peptide transport 1 (PEPTl ) was increased by xylanase + amylase + protease + phytase, and this was increased further when in combination with Enviva Pro. PEPTl is part of a peptide transport system and is responsible for the uptake of a wide range of di- and tri-peptides. The expression of Glucokinase (GCK) was down-regulated by the challenged control but the combination of amylase + phytase or xylanase + amylase + protease + phytase with Enviva Pro produced an up-regulation similar to the unchallenged control. The extent of the up- regulation was greater than when xylanase ⁾- amylase+ protease t phytase were used with Enviva Pro.

A similar pattern was also seen with sucrase iso-maltase (SI) where the combination of Enviva Pro with amylase + phytase or xylanase + amylase + protease + phytase produced a greater up-regulation than both the challenged and unchallenged control. GCK is a key enzyme in glucose metabolism and SI is responsible for hydrolysis of sucrose and iso- maltose, and so has an important role in the digestion and absorption of carbohydrates in animals.

Tight Junction protein 1 (ZOl ) was most highly expressed in the challenged control. A reduction was seen with the enzyme treatments but a greater down-regulation in expression was seen when Enviva Pro was used and particularly so when in combination with xylanase + amylase + protease + phytase which produced a similar level of down-regulation as the non- challenged control. ZOl is a protein that is on the cytoplasmic face of tight junctions, there are various roles for this protein ranging from signal transduction for tight junction assembly to stability of the tight junctions themselves.

The T-cell antigen CD3 (CD3D) was highly expressed in the challenged control. The enzyme alone treatments did reduce expression somewhat but it was significantly down-regulated when in combination with Enviva Pro. The combination of xylanase + amylase + protease+ phytase produced the largest down-regulation of the enzyme treatments, and, when in combination with Enviva Pro, produced an even larger down-regulation close to that seen for the unchallenged control. CD3D is a surface molecule found on T cells and plays an important role in signal transduction during T-cell receptor engagement and is part of the T- cell receptor/CD3 complex.

The alpha amylase (AMY2A) was highly expressed in the unchallenged and challenged controls but the addition of amylase + phytase or xylanase + amylase + protease + phytase resulted in reduced expression, which was further reduced when Enviva Pro was used in combination, particularly for xylanase + amylase + protease + phytase. Chicken alpha amylase is mainly produced in the pancreas and has a major role in starch digestion.

Discussion

The increase in expression of the peptide transporter oligopeptide transporter 1 (PEPTl) when xylanase + amylase + protease + phytase were given, particularly in combination with Enviva Pro, suggests increased availability of peptides and thus an increased requirement of peptide transporters, which indicates a synergistic effect of enzymes and DFMs to increase the adsorption of peptides for the animal which allows for greater growth. Animal performance results of Example 1 support this conclusion. The increase in expression of glucokinase and sucrase isomerase with the combination of amylase + phytase, or xylanase + amylase + protease + phytase, and Enviva Pro suggests that there was increased absorption of glucose, and increased availability of sucrose and isomaltose in the brush border, which indicates a positive interaction between the enzyme and DFMs to increase carbohydrate absorption in the small intestine and thus increase energy availability from the diet. The decrease of glucokinase expression for the challenged control suggests that the Clostridium perfringens challenge caused damage to the mucosa and that addition of Enviva Pro and xylanase + amylase + protease + phytase alleviated this.

The effect of Enviva Pro on reducing the expression of Tight junction protein 1 indicates lower requirement for protein turn over in the intestine, which may be related to a high intestinal integrity. The increased expression in the challenged control, however, suggests that turnover/requirement of the protein was high due to failing intestinal integrity possibly due to the coccidia and Clostridium perfringens infections. The enzymes alone did have some effect on ameliorating this but the additive effect seen with Enviva Pro suggests a greater benefit from the combination. This indicates that Enviva Pro acts to increase intestinal integrity and thus benefit the health of the animal. Increased intestinal integrity, and thus absorptive capacity, may be one of the mechanisms by which the effectiveness of exogenous enzymes is increased when a DFM is present.

The increased expression of T cell antigen CD3 d in the challenged control indicates increased cell-mediated immune response due to the challenge. In these conditions, birds will be undergoing sub-optimal performance because the immune response will demand energy that could be used for growth, and because some birds will experience a systemic disease response. The increased expression of this immunological marker was markedly reversed when Enviva Pro was used alone or in combination with enzymes. Down regulation of immune response in the intestine may be one of the mechanisms by which the effectiveness of exogenous enzymes in nutrient absorption and performance is increased when a DFM is present.

The down-regulation of alpha amylase (AMY2A) production that was seen with the combination of amylase + phytase, or xylanase + amylase + protease + phytase suggests that the chicken is reducing its production of endogenous amylase as a response to the exogenous enzymes supplied. The additive effect seen with Enviva Pro and xylanase + amylase + protease + phytase suggest that the DFM is working synergistically with the exogenous enzymes to allow the bird to utilise the energy that it would have spent producing enzymes for digestion of starch in the diet.

The net effect of a down-regulated immune response and higher intestinal integrity, and a better nutrient digestion and absorption with the combination of enzymes and DFMs, clearly determines enhanced production performance of broiler chickens.

Example 7

Materials and Methods A digestibility trial with broiler chickens was conducted to determine the effects of dietary enzymes and DFM treatments on energy utilisation. A total of 288 day-old, male Ross 308 chicks were obtained from a commercial hatchery and brooded in raised wire battery pens until day 14. Birds were vaccinated with a live coccidia vaccine at hatch (Coccivac-B). Chicks were fed a corn-SBM-DDGS based starter diet. Chicks were provided experimental diets from day 14 until day 21. The feed and water were provided ad-libitum throughout the 21 day period. Six chicks were housed per pen in battery pens located within an environmentally controlled room, where they received supplemental heat starting at 35°C on day-of-age and decreasing 2°C weekly. Light was provided at 23L: 1D. On day 15, chicks were individually weighed, sorted, wing banded and randomly allocated to the experimental units using a completely randomized design. Each treatment consisted of 8 pens per treatment. The study consisted of the following treatments (Table 12). Table 12. Experimental design of Example 7.

Phytase from Buttiauxella.

2 Amylase from Bacillus licheniformis, xylanase from Trichoderma reesei, protease from Bacillus subtilis.

3 Enviva Pro ® is a combination of Bacillus subtilis strains Bs2084, LSSAOl and 15AP4, provided by Danisco A S.

⁴ GalliPro Tect is a DFM comprised by one strain of Bacillus licheniformis (DSM17236).

Enzymes and DFMs were sourced and provided by Danisco in the appropriate mixtures and levels for all experimental treatments. The pens were arranged within the facility to prevent direct contact in order to avoid cross contamination. Birds were fed starter diets (Table 13) in mash form throughout the experimental period. Table 13. Experimental diet composition of Example 7.

Ingredient (%) Starter

Corn 52.94

Corn-DDGS 12.00

Soybean meal 48% 29.38

Animal/ Vegetable Fat Blend 1.08

Salt 0.40

DL Methionine 0.22

Bio-Lys 0.44

Limestone 1.30

Dicalcium Phosphate 1.27

Choline chloride 60 0.10

Vit/Min Premix 0.63

Ti0₂ 0.25

Calculated Nutrient Composition (%)

CP 22.25

ME, kcal/kg 2925

Calcium 0.90

Available phosphorus 0.38

Sodium 0.18

Digestible lysine 1.20

Digestible methionine 0.52

Digestible TSAA 0.85

Digestible threonine 0.75

Clean excreta trays were put in place for the last 2 days and excreta samples were collected by pen on day 21. The collected excreta samples were frozen at -20°C before they were oven dried at 65°C for 3 days to detennine the dry matter (AOAC International, 2005; method 934.01). The feed samples were also corrected to the dry matter basis be measuring 5.0g of each sample and drying them in an oven at 100°C for 24 hrs. The excreta samples were then ground through a 1-mm screen while the feed samples were ground 0.5 -mm screen. Excreta samples and diets were analysed for Ti, DM GE, and N, as per standard procedures. Apparent metabolizable energy (AME) calculation was based on the concentration of the indigestible marker (Ti) and the gross energy of diets and excreta. Appropriate coiTections were made for differences in moisture content. N-corrected AME (AMEn) was determined for zero nitrogen retention by multiplication with 8.22 kcal per gram of nitrogen retained in the body (Hill and Anderson, 1958; J. Nutr. 64:587-603).

Results

Figure 18 shows apparent metabolizable energy corrected by nitrogen retention (AME_n) of 21 d old broiler chickens. Effect of DFM; PO.001 ; Effect of Enzyme; PO.001 ; Effect of DFM x Enzyme; P=0.27; Pooled SEM-32 kcal.

Addition of Xylaiiase, amylase, protease, and phytase, in combination with Enviva Pro or GalliPro Tect resulted in improvements of AME_n versus the control treatment, that were significantly greater compared to the enzymes or the DFMs by themselves. The AME„ increments due to the combination of xylanase, amylase, protease, phytase, and Enviva Pro (235 kcal/kg) or GalliPro Tect (215 kcal/kg) were greater than the addition of the enzymes and the DFM effects when applied separately (152 kcal/kg for Enviva Pro, or 120 kcal/kg for GalliPro Tect), compared to the negative control treatment. Example 8

Materials and Methods

One thousand and four hundred one-day-old Cobb male chicks were purchased from a commercial hatchery. At study initiation, fifty males were allocated to one of seven pens per treatment by blocks. The study consisted of the following treatments (Table 1):

Table 1. Experimental design of Example 8. Treatment Clostridium Phytase¹ Additional enzyme DFM ¹ perfringens

Challenge

1 No 500 None None

FTU/kg

2 Yes 500 None None

FTU/kg

3 Yes 500 None Enviva Pro

FTU/kg (7.5 x lO⁴ FTU/g)

4 Yes 500 Xylanase⁴ (2000 u kg) Enviva Pro

FTU/kg Amylase⁴ (200 u/kg) (7.5 x l O⁴ FTU/g)

Protease⁴ (5000 u kg)

Phytase from E. coli.

Enviva Pro ® is combination of Bacillus subtilis strains Bs2084, LSSAO l and 15AP4, provided by Danisco A/S.

Bird weights by pen were recorded at study initiation, 21 d and termination (42d). The pen was the unit of measure. Broiler diets were fed as crambles (starter) or pellets (grower and finisher). Diets met or exceeded NRC standards (Table 2). The mixer was flushed to prevent cross contamination of diets. All treatment feeds were mixed using a Davis S-20 mixer and pelleted using a California Pellet Mill (cold pellet temperature 65-70 C). Samples were collected from each treatment diet from the beginning, middle, and end of each batch and blended together to confirm enzyme activities and Enviva Pro presence in feed.

Table 2. Experimental diet composition of Example 8.

Ingredient (%) Starter Grower Finisher

Maize 50.959 59.6156 62.7488

Maize DDGS 12 12 12 Soybean Meal 49%CP 30.7176 22.5873 19.4

Choline Chloride 0.06 0.06 0.06

Soy oil 3.0693 2.7035 2.84841

Lysine 0.21 0.2426 0.244

DL-methionine 0.1723 0.1566 0.1341

L-threonine 0.0387 0.0551 0.0564

Salt 0.4668 0.4692 0.47

Limestone 1.4467 1.4501 1.33389

Dicalcium phosphate 0.7346 0.5349 0.571

Vitamin and trace mineral premix 0.125 0.125 0.125

Calculated Nutrient Composition (%)

CP 22.642 19.45 19.45

Energy, mcal/kg 12.761 12.012 12.012

Digestible lysine 1.327 1.124778 1.124778

Digestible methionine 0.53142 0.475425 0.475425

Digestible threonine 0.89401 0.78494 0.78494

Birds received feed ad-libitum appropriate to the treatment from day 0 to 42. Enzymes and Enviva Pro were provided by Danisco in the appropriate mixtures and levels for all experimental treatments. All diets contained 500 FTU of E. coli phytase in the background. The pens were arranged within the facility to prevent direct contact in order to avoid contamination.

A change from starter to grower occurred on day 21. Grower diet was replaced with the finisher diet on day 35. At each feed change, feeders were removed from pens by block, weighed back, emptied, and refilled with the appropriate treatment diet. On the final day of the study, feed was weighed. Pens were checked daily for mortality. When a bird was culled or found dead, the date and removal weight (kg) were recorded. A gross necropsy was performed on all dead or culled birds to determine the sex and probable cause of death. Signs of Necrotic Enteritis were noted. All pens had approximately 4 inches of built up litter with a coating of fresh pine shavings. All birds were spray vaccinated prior to placement: into pens with a commercial coccidiosis vaccine (Coccivac-B). On days 18, 19, and 20 all birds, except Treatment 1 , were dosed with a broth culture of C. perfringens. A field isolate of C. perfringens known to cause Necrotic Enteritis and originating from a commercial broiler operation was utilized as the challenge organism. Fresh inoculum was used each day. The titration levels were approximately 1.0 X 10^8"9. Each pen received the same amount of inoculum. The inoculum was administered by mixing into the feed found in the base of the tube feeder.

Sample Collection

On day 21. a total of 8 birds per treatment (1-2 birds per pen) were euthanised and the total gastrointestinal tract from below the gizzard to the ileal-cecal junction was collected from each bird and sent overnight on ice to the laboratory. The samples were further dissected in the laboratory to obtain a 20 cm portion of the jejunum surrounding the Meckle's diverticulum; the remainder of the intestinal tract was discarded. The sections were rinsed with 0.1% peptone to remove the intestinal contents and opened longitudinally to expose the epithelial lining. The sections were masticated in 99 ml of 0.1%) peptone at 7.0 strokes/s for 60 s to release mucosa-associated bacterial cells. Bacteria were harvested from the masticated solution by centrifugation at 12,000 x g for 10 minutes. The resultant bacterial pellet was resuspended in 10 ml of MRS broth + 10%> glycerol, flash-frozen in liquid nitrogen, and stored at -20°C until further analysis.

DNA isolation

Genomic DNA was isolated from all samples by phenol chloroform extraction and purified using Roche Applied Science High Pure PGR Template Purification Kit (Roche Diagnostics Corp., Indianapolis, IN). Samples were randomly pooled in pairs at the DNA level after extraction, for a total of four samples per treatment.

Pyrosequencing

Bacterial tag-encoded FLX amplicon pyrosequencing was performed as described by Dowd (Dowd et al. 2008; BMC Microbiol. 8, 125). An equivalent amount of DNA isolated from the intestinal mucosa from each bird was analyzed in pooled samples containing DNA from two birds. The VI -V3 region of the 16S rRNA gene was amplified in each sample using the primers 28 F (5'- GAGTTTGATCNTGGCTCAG) and 519R (5'- GTNTTACNGCGGCKGCTG). Following sequencing, raw data was screened and trimmed based on quality. Sequences were sorted by individual samples based on barcode sequences. Barcode tags were removed and non-bacteria ribosomal sequences were removed. The bacterial community composition was determined using BlastN comparison to a quality controlled and manually curated database derived from NCBI. The relative abundance of each bacterial ID was determined for each sample. Data was compiled at each taxonomic level using NCBI nomenclature.

Statistical analysis

For performance data means were separated using pair wise t-tests. Significant differences were considered at P<0.05. Pens were used as the experimental unit.

Genus level identifications were used for the analysis of the pyrosequencing data. The relative abundance of each genus was calculated and used for the analysis. The results were analysed using a categorical model analysis and then a Chi-square probability calculated using JMP 8.0.2 (SAS institute, Gary, NC), where each sample representing two birds was considered an experimental unit.

Results:

The combination of Enviva Pro with xylanase, amylase, protease + phytase reduced FCR (g BW gain / g feed intake) compared to the challenged control treatment and the use of Enviva Pro and phytase alone. Feed conversion ratio was reduced by the combination to the level of the unchallenged control + phytase.

Figure 20 shows relative abundance oi Lactobacillus spp. at 21d in the jejunal mucosa of broiler chickens, ChSq O.0001. Figure 20 shows the relative abundance of Lactobacillus spp. in comparison to other species in the jejunal mucosa of broilers at 21days in a necrotic enteritis challenge model. The proportion of Lactobacilli was reduced in the challenged control in comparison to the unchallenged control. The combination of Enviva Pro, xylanase, amylase, protease + phytase increases the proportion of Lactobacilli more so than Enviva Pro and phytase alone and the challenged control.

Lactobacilli are widely used as probiotics for both human and animal use (Patterson and Burkeholder 2003; Poult Sci 82 (4) 627-31) and have been documented to improve gut health to a level that could be comparable to antibiotic growth promoters (Awad et al. 2009 Poult Sci 88 (1 ) 49-56). Thus by increasing the proportion Lactobacilli in the gut microbiota, the combination of Enviva Pro, xylanase, amylase, protease + phytase can improve gut health and positively impact feed efficiency.

All publications mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described methods and system of the present invention will be apparent to those skilled in the art without departing from the scope and spirit of the present invention. Although the present invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in biochemistry and biotechnology or related fields are intended to be within the scope of the following claims.

Claims

1. A feed additive composition comprising a direct fed microbial in combination with a protease, a xylanase, an amylase and a phytase.

2. A feed additive composition according to claim 1 wherein the direct fed microbial is an antipathogen direct fed microbial.

3. A feed additive composition according to claim 1 or claim 2 wherein the direct fed microbial is a viable bacterium.

4. A feed additive composition according to any one of claims 1 to 3 wherein the direct fed microbial comprises a bacterium from one or more of the following genera: Lactobacillus,

Lactococcus, Streptococcus, Bacillus, Pediococcus, Enterococcus, Leuconostoc, Carnobacterium, Propionibacterium, Bifidobacterium, Clostridium and Megasphaera and combinations thereof.

5. A feed additive composition according to any one of the preceding claims wherein the direct fed microbial comprises a bacterium from one or more of the following species:

Bacillus subtilis, Bacillus licheniformis, Bacillus amyloliquefaciens, Enterococcus , Enterococcus spp, and Pediococcus spp, Lactobacillus spp, Bifidobacterium spp, Lactobacillus acidophilus, Pediococsus acidilactici, Lactococcus lactis, Bifidobacterium bifidum, Propionibacterium thoenii, Lactobacillus farciminus, lactobaciUus rhamnosus, Clostridium butyricum, Bifidobacterium animalis ssp. animalis, Lactobacillus reuteri, Bacillus cereus, Lactobacillus salivarius ssp. salivarius, Megasphaera elsdenii, Propionibacteria sp and combinations thereof.

6. A feed additive composition according to any one of the preceding claims wherein the direct fed microbial is one or more of the following strains: Bacillus subtilis strains 3A-P4 (PTA-6506); 15A-P4 (PTA-6507); 22C-P1 (PTA-6508); 2084 (NRRL B-500130); LSSA01 (NRRL-B-50104); BS27 (NRRL B-50105); BS 18 (NRRL B-50633); and BS 278 (NRRL B- 50634).

7. A feed additive composition according to any one of the preceding claims wherein the direct fed microbial is in the form of an endospore.

8. A feed additive composition according any one of the preceding claims wherein the xylanase is an endo-l,4-P-d-xylanase or a 1 ,4 β-xylosidase preferably an endo- 1 ,4-P-d- xylanase.

9. A feed additive composition according to any one of the preceding claims wherein the xylanase is from Bacillus, Trichoderma, Thermomyces, Aspergillus, Penicillium and Humicola.

10. A feed additive composition according to any one of the preceding claims wherein the protease is a subtilisin, a bacillolysin, an alkaline serine protease, a keratinase or a

Nocardiopsis protease.

1 1. A feed additive composition according to any one of the preceding claims wherein the phytase is a 6-phytase or a 3 -phytase.

12. A feed additive composition according to claim 1 1 wherein the phytase is a 6-phytase.

13. A feed additive composition according to any one of the preceding claims wherein the phytase is an E. coli phytase or a Buttiauxella phytase or Hafnia phytase or a Citrobacter phytase or a Aspergillus phytase or a Penicillium phytase or a Trichoderma phytase or a Hansenula phytase.

14. A feed additive composition according to any one of the preceding claims wherein the amylase is selected from one or more of the group consisting of: an a-amylase, a G4-forming amylase, a β-amylase and a y-amylases.

15. A feed additive composition according to claim 14 wherein the amylase is an a-amylase.

16. A feed additive composition according to any one of the preceding claims wherein the amylase is from Bacillus licheniformis, B. amyloliquefaciens, Trichoderma spp. or Aspergillus spp.

17. A feed additive composition according to any one of the preceding claims wherein the phytase is present at a dosage of between 200FTU/g feed additive composition and 10000 FTU/g feed additive composition.

18. A feed additive composition according to any one of the preceding claims wherein the amylase is present at a dosage of between 50 AU/g feed additive composition and 20000

AU/g feed additive composition.

19. A feed additive composition according to any one of the preceding claims wherein the xylanase is present at a dosage of between 500XU/g feed additive composition and 40000XU/g feed additive composition.

20. A feed additive composition according to any one of the preceding claims wherein the protease is present at a dosage of lOOOPU/g feed additive composition and 60000PU/g feed additive composition. 106

21. A feed additive composition according to any one of the preceding claims wherein the DFM is present at a dosage of 3.75x 10⁷CFU/g feed additive composition and lx l OⁿCFU/g feed additive composition.

22. A method for improving the performance of a subject or for improving digestibility of a raw material in a feed (e.g. nutrient digestibility, such as amino acid digestibility), or for improving nitrogen retention, or for improving the subjects resistance to necrotic enteritis or for improving feed conversion ratio (FCR) or for improving body weight gain in a subject or for improving feed efficiency in a subject or for modulating (e.g. improving) the immune response of the subject, or for promoting the growth of beneficial bacteria in the gastrointestinal tract of a subject or for reducing populations of pathogenic bacteria in the gastrointestinal tract of a subject, or for reducing nutrient excretion in manure, which method comprising administering to a subject a direct fed microbial in combination with a protease, a xylanase, an amylase and a phytase.

23. A method according to claim 22 comprising administering the feed additive composition according to any one of claims 1-21.

24. A method according to claim 22 or 23 wherein the direct fed microbial is an antipathogen direct fed microbial.

25. A method according to any one of claims 22-24 wherein the direct fed microbial is a viable bacteria.

26. A method according to any one of claims 22 to 25 wherein the direct fed microbial comprises a bacterium from one or more of the following genera: Lactobacillus, Lactococcus, Streptococcus, Bacillus, Pediococcus, Enterococcus, Leuconostoc, Carnobacterium, Propionibacterium, Bifidobacterium, Clostridium and Megasphaera and combinations thereof.

27. A method according to any one of claims 22-26 wherein the direct fed microbial comprises a bacterium from one or more of the following species: Bacillus subtilis, Bacillus licheniformis, Bacillus amyloliquefaciens, Enterococcus , Enterococcus spp, and Pediococcus spp, Lactobacillus spp, Bifidobacterium spp, Lactobacillus acidophilus, Pediococsus acidilaclici, Lactococcus lactis, Bifidobacterium bifidum, Propionibacterium thoenii, Lactobacillus farciminus, lactobacillus rhamnosus, Clostridium butyricum, Bifidobacterium animalis ssp. animalis, Lactobacillus reuteri, Bacillus cereus, Lactobacillus salivarius ssp. salivarius, Megasphaera elsdenii, Propionibacteria sp and combinations thereof.

28. A method according to any one of claims 22-27 wherein the direct fed microbial is one or more of the following strains: Bacillus subtilis strains 3A-P4 (PTA-6506); 15A-P4 (PTA- 6507); 22C-P1 (PTA-6508); 2084 (NRRL B-500130); LSSAOl (NRRL-B-50104); BS27 (NRRL B-50105); BS 1 8 (NRRL B-50633); and BS 278 (NRRL B-50634).

29. A method according to any one of claims 22-28 wherein the direct fed microbial is in the form of an endo spore.

30. A method according to any one of claims 22-29 wherein the xylanase is an endo- 1 ,4-[3-d- xylanase or a 1 ,4 β-xylosidase preferably an endo- l ,4- -d-xylanase.

31. A method according to any one of claims 22-30 wherein the xylanase is from Bacillus, Trichoderma, Thermomyces, Aspergillus, Penicillium and Humicola.

32. A method according to any one of claims 22-31 wherein the protease is a subtilisin, a bacillolysin, an alkaline serine protease or a keratinase or a Nocardiopsis protease.

33. A method according to any one of claims 22-32 wherein the phytase is a 6-phytase or a 3- phytase.

34. A method according to claim 33 wherein the phytase is a 6-phytase.

35. A method according to any one of claims 22-34 wherein the phytase is an E. coli phytase or a Buttiauxella phytase or Hafnia phytase or Citrobacter phytase or a Aspergillus phytase or a Penicillium phytase or a Trichoderma phytase or a Hansen la phytase.

36. A method according to any one of claims 22-35 wherein the amylase is selected from one or more of the group consisting of: an -amylase, a G4-forming amylase, a β-amylase and a γ- amylases.

37. A method according to any one of claims 22-36 wherein the amylase is an a-amylase.

38. A method according to any one of claims 22-37 wherein the amylase is from Bacillus licheniformis, B. amyloliquefaciens, Trichoderma spp. or Aspergillus spp.

39. Use of a direct fed microbial in combination with a protease, a xylanase, an amylase and a phytase for improving the performance of a subject or for improving digestibility of a raw material in a feed (e.g. nutrient digestibility, such as amino acid digestibility) or for improving nitrogen retention) or for improving the subject's resistance to of necrotic enteritis or for improving feed conversion ratio (FCR) or for improving weight gain in a subject or for improving feed efficiency in a subject or for modulating (e.g. improving) the immune response of the subject or for promoting the growth of beneficial bacteria in the gastrointestinal tract of a subject or for reducing populations of pathogenic bacteria in the gastrointestinal tract of a subject, or for reducing nutrient excretion in manure.

40. Use according to claim 39 wherein the feed additive composition according to any one of claims 1 -21 is used.

41 . Use according to any one of claims 39-40 wherein the direct fed microbial is an anti pathogen direct: fed microbial.

42. Use according to any one of claims 39-41 wherein the direct fed microbial is a viable bacterium.

43. Use according to any one of claims 39-42 wherein the direct fed microbial comprises a bacterium from one or more of the following genera: Lactobacillus, Lactococcus, Streptococcus, Bacillus, Pediococcus, Enter ococcus, Leuconostoc, Carnobacterium, Propionibacterium, Bifidobacterium, Clostridium and Megasphaera and combinations thereof.

44. Use according to any one of claims 39-43 wherein the direct fed microbial comprises a bacterium from one or more of the following species: Bacillus subtilis, Bacillus licheniformis, Bacillus amyloliquefaciens, Enterococcus , Enterococcus spp, and Pediococcus spp, Lactobacillus spp, Bifidobacterium spp, Lactobacillus acidophilus, Pediococsus acidilactici, Lactococcus lactis, Bifidobacterium bifidum, Propionibacterium thoenii, Lactobacillus farciminus, lactobacillus rhamnosus, Clostridium butyricum, Bifidobacterium animalis ssp. animalis, Lactobacillus reuteri, Bacillus cereus, Lactobacillus salivarius ssp. salivarius,

Megasphaera elsdenii, Propionibacteria sp and combinations thereof.

45. Use according to any one of claims 39-44 wherein the direct fed microbial is one or more of the following strains: Bacillus subtilis strains 3A-P4 (PTA-6506); 15A-P4 (PTA-6507);

22C-P1 (PTA-6508); 2084 (NRRL B-500130); LSSA01 (NRRL-B-50104); BS27 (NRRL B-

50105); BS 18 (NRRL B-50633); and BS 278 (NRRL B-50634).

46. Use according to any one of claims 39-45 wherein the direct fed microbial is in the form of an endospore.

47. Use according to any one of claims 39-46 wherein the xylanase is an endo-l ,4- -d- xylanase or a 1 ,4 β-xylosidase preferably an endo- l,4- -d-xylanase.

48. Use according to any one of claims 39-47 wherein the xylanase is from Bacillus, Trichoderma, Thermomyces, Aspergillus, Penicillium and Humicola.

49. Use according to any one of claims 39-48 wherein the protease is a subtilisin, a bacillolysin, an alkaline serine protease or a keratinase or a Nocardiopsis protease.

50. Use according to any one of claims 39-49 wherein the phytase is a 6-phytase or a 3- phytase.

51 . Use according to claim 50 wherein the phytase is a 6-phytase.

52. Use according to any one of claims 39-51 wherein the phytase is an /·:^'. coli phytase or a Buttiauxella phytase or Hafnia phytase or Citrobacter phytase or a Aspergillus phytase or a Penicillium phytase or a Trichoderma phytase or a Hansenula phytase.

53. Use according to any one of claims 39-52 wherein the amylase is selected from one or more of the group consisting of: an a-amylase, a G4-forming amylase, a β-amylase and a γ- amylases.

54. Use according to any one of claims 39-53 wherein the amylase is an a-amylase.

55. Use according to any one of claims 39-54 wherein the amylase is from Bacillus licheniformis, B. amyloliquefaciens, Trichoderma spp. ox Aspergillus spp.

56. A kit comprising a direct fed microbial, a protease, a xylanase, an amylase, a phytase and instructions for administration.

57. A kit according to claim 56 wherein said kit comprises the feed additive composition according to any one of claims 1-21.

58. A kit according to any one of claims 56-57 wherein the direct fed microbial is an antipathogen direct fed microbial.

59. A kit according to any one of claims 56-58 wherein the direct fed microbial is a viable bacterium.

60. A kit according to any one of claims 56-59 wherein the direct fed microbial comprises a bacterium from one or more of the following genera: Lactobacillus, Lactococcus,

Streptococcus, Bacillus, Pediococcus, Enter ococcus, Leuconostoc, Carnobacterium, Propionibacterium, Bifidobacterium, Clostridium and Megasphaera and combinations thereof.

61. A kit according to any one of claims 56-60 wherein the direct fed microbial comprises a bacterium from one or more of the following species: Bacillus subtilis, Bacillus licheniformis,

Bacillus amyloliquefaciens, Enterococcus , Enterococcus spp, and Pediococcus spp, Lactobacillus spp, Bifidobacterium spp, Lactobacillus acidophilus, Pediococsus acidilactici, Lactococcus lactis, Bifidobacterium bifidum, Propionibacterium thoenii, Lactobacillus farciminus, lactobacillus rhamnosus, Clostridium butyricum, Bifidobacterium animalis ssp. animalis, Lactobacillus reuteri, Bacillus cereus, Lactobacillus salivarius ssp. salivarius, Megasphaera elsdenii, Propionibacteria sp and combinations thereof.

62. A kit according to any one of claims 56-61 wherein the direct fed microbial is one or more of the following strains: Bacillus subtilis strains 3A-P4 (PTA-6506); 15A-P4 (PTA-6507); 22C-P1 (PTA-6508); 2084 (NRRL B-500130); LSSA01 (NRRL-B-50104); BS27 (NRRL B- 50105); BS 18 (NRRL B-50633); and BS 278 (NRRL B-50634).

63. A kit according to any one of claims 56-62 wherein the direct fed microbial is in the form of an endo spore.

64. A kit according to any one of claims 56-63 wherein the xylanase is an endo- 1 ,4-P-d- xylanase or a 1 ,4 β-xylosidase preferably an endo-l ,4-P-d-xylanase.

65. A kit according to any one of claims 56-64 wherein the xylanase is from Bacillus, Trichoderma, Thermomyces, Aspergillus, Penicillium and Humicola.

66. A kit according to any one of claims 56-65 wherein the protease is a subtilisin, a bacillolysin, an alkaline serine protease or a keratinase or a Nocardiopsis protease.

67. A kit according to any one of claims 56-66 wherein the phytase is a 6-phytase or a 3- phytase.

68. A kit according to claim 67 wherein the phytase is a 6-phytase.

69. A kit according to any one of claims 56-68 wherein the phytase is an E. coll phytase or a Buttiauxella phytase or Hafnia phytase or Citrobacter phytase or an Aspergillus phytase or a

Penicillium phytase or a Trichoderma phytase or a Hansenula phytase.

70. A kit according to any one of claims 56-69 wherein the amylase is selected from one or more of the group consisting of: an a-amylase, a G4-forming amylase, a β-amylase and a γ- amylases.

71. A kit according to any one of claims 56-70 wherein the amylase is an a-amylase.

72. A kit according to any one of claims 56-71 wherein the amylase is from Bacillus licheniformis or, B. amyloliquefaciens, Trichoderma spp. or Aspergillus spp.

73. A method of preparing a feed additive composition, comprising admixing a direct fed microbial with a protease, a xylanase, an amylase and a phytase and (optionally) packaging.

74. A feed comprising a feed additive composition according to any one of claims 1-21.

75. A feed according to claim 74 wherein the phytase is present at a dosage of between 400FTU/kg feed and 1000 FTU//kg feed.

76. A feed according to claim 74 or claim 75, wherein the amylase is present at a dosage of between 100 AU/kg feed and 2000 AU/kg feed.

77. A feed according to any one of claims 74-76 wherein the xylanase is present at a dosage of between lOOOXU/kg feed and 4000XU/kg feed.

78. A feed according to any one of claims 74-77 wherein the protease is present at a dosage of between 2000PU/kg feed to 6000PU/kg feed.

79. A feed according to any one of claims 74-77 wherein the DFM is present at a dosage of 7.5x 10⁴CFU/kg feed and l x l0⁷CFU/kg feed.

80. A method of preparing a feedstuff comprising admixing a feed component with a feed additive composition according to any one of claims 1 -21 .

81. A premix comprising a feed additive composition comprising a direct fed microbial in combination with a protease, a xylanase, an amylase and a phytase, and at least one mineral and/or at least one vitamin.

82. A premix comprising a feed additive composition according to any one of claims 1 -21 in combination with at least one mineral and/or at least one vitamin.

83. A feed additive composition according to any one of claims 1-21 for preventing and/or treating coccidiosis and/or necrotic enteritis in a subject.

84. A method of preventing and/or treating necrotic enteritis and/or coccidiosis wherein an effective amount of a feed additive composition according to any one of claims 1-21 is administered to a subject.

85. A feed additive composition or feed or kit or method or use or premix as defined generally herein with reference to the Figures and the Examples.